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Abstract 
Introduction' Famil ial hypercholesterolemia is a senous health problem in most 
populations including Arabs leading to increased morbidity and mortal ity. This illness is 
hereditary in an autosomal dominant manner affecting 1 in 500 people and is mainly 
caused by mutations in LDLR and Apolipoprotein B genes. The manifestations of this 
di  ease are pre entable by medical intervention and changes to l ife style .  However, 
prevention i only pos ible if detection of the disease is made early in l ife. Moreover, the 
W HO strongly recommends that governments establish programs for identifying and 
registering famil ial hypercholesterolemia patients and their famil ies. There are no 
molecular data available on this il lness in  the UAE despite cl inical and biochemical studies 
indicating high prevalence of hypercholesterolemia in UAE Arab populations. Objectives; 
thi project aimed to identify the molecular basis of famil ial hypercholesterolemia in UAE 
Arab populations. Materials and methods; Blood samples were col lected from suspected 
patients with h igh levels  of cholesterol (>5mmollL) fol lowed by genomic DNA i solation 
and peR ampl ification of all LDLR gene exons and splice sites and exons 26 and 29 of the 
Apo B 1 00 gene. PCR products were first analyzed and isual ized by agarose gel 
electrophoresis and then cleaned using a mixture of Exonuclease and Shrimp Alkal ine 
Phosphatase enzymes (EXO- SAP) fol lowed by direct DNA sequencing. The sequences 
obtained were compared to the publ i shed sequences for the two genes using the 
CLU ST AL W al ignment programme. In addition, we generated by site-directed 
mutagenesis some of the publ i shed missense mutations responsible for fami l ial 
hypercholesterol emia in  other populations and studied their subcellular local ization by 
confocal microscopy. Results and d iscussion; Sequencing of the coding regions and 
splice sites of al l LDLR exons and exon s  26 and 29 from Apo B I 00 genes from over 40 
hypercholesterolemic UAE individuals fai led to reveal any clear pathogenic mutations. 
However, our analysis revealed 1 1  different polymorph isms reported with known ethnic 
backgrounds and we were able to calculate the al lele and genotypes frequencies of those 
polymorphisms in UAE population . The failure to detect any pathogenic mutation in a 
representative group of hypercholesterolemic individuals from the UAE might indicate that 
thi s  condition is caused by other factors including possibly other genetic and/or 
environmental factors. In support of this notion is the lack of any reports on cases of 
11 
homoz gous famil ial hyperchole terolemia in UAE population. This  would be expected in 
the l ight of the ery high rates consanguineous marriages (>50%) within most famil ies of 
the UAE population. The confocal microscopy data confrrmed that some of the studied 
mutat ions re ul ted in trafficking defects of the LDLR protein. 
Key J-Vords: famil ial hypercholesterolemia (FH), LDLR gene, ApoB100 gene, 
thero clero is .  
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CHAPTER I 
INTRODUCTION 
- 1 -
1 . 1  Introduction 
1. 1. Hypercholesterolemia and Coronary Heart Disease 
Hypercholesterolemia refers to a condition where the level of cholesterol in the blood 
stream is higher than normal .  TI le  normal range for total b lood cholesterol is between 1 40 
and 200mg per deci l i ter (mg/dL) .  Levels between 200 and 240 mg/dL indicate moderate 
hypercholesterolemia and level above 240 mg/dL indicate high hypercholesterolemia. 
While total cholesterol Ie el is an important and a good indicator of the risks associated 
with hypercholesterolemia, it does not give a clear picture of the situation. This of course 
is due to the fact that there are two main forms of cholesterol :  the low density l ipoproteins 
(LDL) and the h igh density l ipoproteins (HDL) cholesterol .  Cholesterol associated with 
HDL is general ly considered to be the "good" cholesterol, while LDL-cholesterol is 
considered to be the "bad" cholesterol .  In addition, triglycerides which are a third type of 
fatty material found in the blood stream may have a role in  the risks associated with 
hypercholesterolemia. I t  appears that as triglyceride levels rise, the levels of HDL 
cholesterol fal l .  The complex interactions of these three types of lipids in  the blood of an 
individual are an important risk factor for the development of coronary heart diseases. 
It is well establ ished that an elevated level of plasma LDL is a serious problem which 
can lead to coronary heart disease resulting in increased morbidity, mainly due to 
atherosclerosis formation. Atherosclerosis is a condition in which cholesterol-rich plaques 
build up along the arterial walls (Goldbourt et al. , 1 986). P laque formation starts to 
develop when an injury occurs in the endothelia l  layer l ining the artery wall as shown in 
fi gure 1 .  In response to injury the macrophages become engorged with the LDL and they 
initiate the development of an atherosclerotic lesion, which over t ime can grow into an 
atherosclerotic p laque (Goldbourt et aI. , 1 986). Extensive p laque formation may lead to 
b lockage of the blood flow leading to heart attack. 
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Plaque formation and growth 
Cholesterol pa cles I Itrate e 
da a ed In er lining 0 t� ar1ery. 
Artmy 
A plaque develops In the a ery. 
o estero! and olMe 
9 bloc d 
art ry 
The p aq e continues to go . 
b g blood no th oug the 
Chof t rol p riel s 
d op tng 
o a art ry 
(50% bloc 
Blood clot 
The p aq e ptures and a b oed 
clot for s. corrpletely bloc ng 
b oed ow roug e te 
Figu re 1 .  An Il l ustration of A rterial Plaque Formation. Plaque fonnation starts \vith 
the accumu lation of fats on the arterial wall mainly the LDL particles the plaque cont inue 
to grow with t ime and may block the blood flow through the artery. 
Adapted from: http://w\vw.virtualmedicalcenter.com 
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1.2. Chole terol Structure, Biosynthesis and Homeostasis 
holesterol (Figure _ ) is a oft waxy substance that is a natural component of the fats 
and lipoproteins in the bloodstream and it is also present in all the cells of the body. 
ChoJe terol comes from two main sources, either from the diet that we consume or it can 
be bio ynthesized in the body by l iver cell s  (Matthan el al. 2004) .  In the cel l ,  cholesterol 
i biosynthe ized ria the mevalonate pathway (Figure 3) and is an essential component of 
mammalian cell membrane where i t  is required to establ ish proper membrane 
penneability and fluidity. In addition, cholesterol has many cellular functions including 
proper functioning of virtually all  cel ls including those in the brain, nervous system, 
mu cle, skin, l iver , intestines and heart .  It is also considered as an essential precursor for 
the production of many hormones, vitamin D and the bile acids. (Yokoyama, 2000). 
Only moderate amounts of cholesterol in the blood stream are needed to meet all our 
cel lular requ irements. However , if  the blood contains elevated levels of cholesterol in the 
form of LDL, it may lead to atherosclerosis and CHD as shown in Figure I (Yokoyama, 
2000). 
Cholesterol 
HO 
Figure 2. The Chemical Structure of Cholesterol .  !UP AC name: ( l OR, 1 3R)- l 0, 1 3-
dimethyl- 1 7  -(6-methylb eptan-2-yl)-2,3 ,4,7 8 9 , 1 1 , 1 2, 1 4, 1 5 , 1 6, 1 7-dodecahydro- l H­
cyclopenta [a]phenantbren-3-01). Adapted from: http://foodspace.wordpress.com 
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Figu re 3. The Cel l u lar Sou rces of Cholesterol .  Cellular cholesterol is derived from 
either 3-h}droxy 3-methylglutaryl-CoA (HMG-CoA) of the mevalonate pathway or from 
pia ma LDL as shown in the above diagram. HMG-CoA is converted to mevalonate b) 
HMG-CoA reductase, the rate-limiting enzyme at the apex of the mevalonate pathway. 
Me alonate is then converted to isopentenyl pyrophosphate (isopentenyl-PP), which is 
subsequentl} con erted to farnesyl pyropho phate (fame yl-PP) through a series of 
enzymatic reaction . After addition of isopentenyl-PP, farnesyl-PP can be con erted to 
geranylgeranyl pyrophosphate (geranylgernayl-PP), or alternatively farnesyl-PP can be 
com erted to cholesterol via a eries of enzymatic reactions. Adapted from 
http://wV\w .nature.com/ng/journallv22/n2/images/ng0699 _122.gif 
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The major organ for cholesterol catabolism is the liver and the steroidooenic cell in eo , 
which cholesterol can be used a a precur or for producing bi le acids or steroids 
hormones (Yokoyama, 2000). The l iver, for example, produces about 1 gram of 
cholesterol per day. The mechanisms of regulating cholesterol absorbance, biosynthesis, 
clearance and intracellular trafficking are very complicated and important for cholesterol 
hom eo tasis in the body. Cholesterol homeostasis is mainly regulated by two mechanisms 
which are controlled by two main proteins the 3 -hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reducta e (Figure 3 )  and the low-density lipoprotein (LDL) receptor (LDLR) 
(Is andiu ef 01., 2004) HMG-CoA reductase work as a rate- limiting enzyme involved in 
cholesterol b iosynthesis via the mevalonate pathway whereas the LDL receptor regulates 
the catabol ism of LDL by the l iver by promoting the clearance of the LDL part icles from 
the blood stream. 
1.3. Lipoproteins and their roles in cholesterol transport and metabolism 
Lipoproteins are classes of conjugated proteins consisting of a protein combined with 
lipids. The functioning of l ipoproteins is to transfer the insoluble lipids, such as 
cholesterol, steroid hormones bi le, triglycerides and cholesterol through the blood stream 
and deliver them to the t issue where the body uses it (Familial Hypercholesterolemia, 
2005) .  Due to Cholesterol i nsolubi l ity in  water, it should be transported through other 
molecules so that the body cells can benefit from it. Lipoproteins al low the transport of 
hydrophobic cholesterol and other lipids through aqueous plasma (Rudenko et of, 2003) .  
Lipoproteins partic les are composed of  a core of triglycerides and cholesterol esters and a 
surface layer of phospholipids and free cholesterol, into which one or more proteins 
(apolipoproteins) are inserted . C lassification of l ipoproteins is based on their specific 
density, which reflects their protein and lipid composition. Low-density l ipoprotein (LDL) 
is particularly rich in cholesterol (see Figure 4) (Rudenko el aZ, 2003).  Two third of the 
body cholesterol are packaged within the LDL (Brown ef 01 1 979), 
- 5 -
Apoprot91n 8'100 LDL 
Figu re 4. LDL composit ion and St ructu re. Schematic illustration of LDL composition 
and structure. It composed of a core of cholesterol esters and a urface layer of 
phospholipids and free cholesterol and Apoprotein BI00. 
Adopted from http://\',,ww.cholesterol-and-health.org.uklhdl-Idl.htm I 
Lipoproteins vary by ize and density and lipid content. They are cIa sified upon 
their density into six cIa es (Chylomicron , VLDL, IDL, LDL, HDL and Lp(a» (Figure 
5; Table I; Familial Hypercholesterolemia, 2005 ) .  In addition, each lipoprotein fraction 
differs in its content of the arious apolipoproteins (Familial Hypercholesterolemia, 2005 ) .  
All the classes of lipoprotein are alike and hare a general structure; a core of the 
lipoprotein contains primaril cholesterol ester and triglyceride surrounded by a coating 
of protein and phospholipids that are amphipathic (with polar and nonpolar regions) and 
integrated apolipoproteins (Familial Hypercholesterolemia, 2005).  Below i a brief 
description of the varioLis types of lipoproteins: 
Chylomicrons. Chylomicrons are derived from the small intestine and mainl transpol1 
dietar) lipids. Chylomicrons consi t of 98% lipid and are large in size with the lowe t 
density among the lipoproteins. They contain the following Apoproteins: 
- 6 -
Apo B-48: Receptor binding 
Apo C-ll : Lipoprotein l ipase activator 
Apo E: Remnant receptor binding 
Vel) Low Density Lipoprotein (VLDL). VLDL are Synthesized in l iver and their main 
function is to transport endogenou triglycerides and they consist of 90% l ipid and 1 0% 
protein and contain the following Apoproteins:  
Apo B- 1 00: Receptor binding 
Apo C-ll : LPL activator 
Apo E: Remnant receptor b inding 
Illtermediate Dellsity Lipoprotein (IDL). IDL are synthesized from VLDL during VLDL 
degradation, tbey transport triglyceride and precursor to LDL, and they contain the 
fol low ing Apoproteins: 
Apo B- 1 00: Receptor binding 
Apo C-ll : LPL activator 
Apo E:Receptor binding 
Low Density Lipoprotein (LDL). LDL is  synthesized from ID L, tbeir main function is to 
transport cholesterol ,  they consist of 79% l ipid and 21 % Protein ,They have Apo B- I OO: 
receptor binding, 
High Density Lipoprotein (HDL). HDL is synthesized in the l iver and intestine, they 
transport tbe cholesterol from the b lood to the l iver, tbey contain 52% protein, 48% l ipid, 
3500 C & CE and the fol lowing Apo proteins are available in the HDL l ipoprotein 
Apo A:Activates lecithin-cholesterol acyltransferase (LCAT) 
Apo C : Activates LPL 
Apo E :Remnant receptor binding 
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Classification of Lipoproteins 
··Bad" 
(Non-HDL) 
VLDL 
Very Low 
D n.slt>­
L.lpopf'oteln 
70 run 
tDL 
Intermediate 
Density 
Lipoprotein 
40 ...... 
LDL 
Low 
Oen.tty 
LI�n 
20_ 
"Good" 
HDL 
High 
Density 
Lipoprotein 
10 nn> 
rnO , com 
Figu re 5. Class ification of Lipoproteins: Diagram showing the lipoproteins structure 
and ize (Chylomicron which are large lipoprotein transfer the cholesterol from the 
intestine to the tissue, VLDL Synthe ized in the liver and transport cholesterol to tissues. 
IDL are ) nthe ized from VLDL during VLDL degradation LDL transport cholesterol to 
the ti sue HDL produced in the liver and bring the cholesterol to the liver to be converted 
into bile acid. Adopted from: http://wW\v.medscape.com 
r -...,-. -
---r - -,-
-
'I 
Ch) lomicrons 
VLDL 
IDL 
LDL 
HDL 
Intestine 90- 1 00 <0.95 1 -2 
Liver 30-90 0.95- 1 .006 7- 1 0  
VLDL 25-30 1 . 006- l .0 1 9  II 
VLDL 20-25 1 .0 1 9- 1 .063 2 1  
Intestine and 
7. 5-20 1 . 063- 1 .2 1 0  33-57 
VLDL 
Table 1 .  Com position of the Lipoprotein.  
(Adopted from: Murray et al., 1 993 ) 
- 8 -
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90-93 
89 
79 
43-67 
1.4. Endocytosis of Low Dell ity Lipoprotein Particles 
Binding of LDL to LDL receptor (LDLR) eApre ed on the cell urface lead to 
internalization of th LDLR- LDL complex as hov. n in Figure 6. Endocytosi of LDLR­
LDL complex i carried out by clathrin-mediated endoc) tosi . Clathrin coated pit are 
p cializ d region of th pIa rna membrane that are lined on the cytopla mic surface by a 
protein called clathrin (Burden ef ai, 2004). After the LDLR bind to LDL, the coated pits 
internalize and the clathrin coat are remo ed by de-coating in ide the cell . MUltiple 
endoc) tic ve icle fuse to form endo omes where the pH begin to fall belO\ 6.5 (Albert 
ef aI, 2001 ). At thi acidity, the LDL di sociate from the LDLR thus allowing the LDLR 
return to the cell urface. LDL that is dissociated from the receptor is del ivered to the 
I) so ome \\ here h) drolytic enz) mes degrade LDL for metabolic use including cholesterol 
(Albert et aI, 200 I ). 
Figu re 6. E ndocytosis of the LDL pa rticles. Shows the receptor mediated endoc) tosis 
of the LDL Particles. Adapted from: http://\ww-als.lbl.go Ipics/56chloresterol2.jpg 
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1.5. LDLR Gene alld Protein Structure 
The gene for human LDL r ceptor i about 45 Kilo ba e (Kb) of D located on 
the hort aml of chromo ome 19, and con i t of 1 8  Exon and 1 7  intron (Heath el at, 
2001 ). 
--�·l�l�·l\·JY � ---""=- --===- --=-
Fig u re 7. Ch romo oma l location of t.he LDLR gene. The LDLR gene is located on the 
hort (p) arm of chromo ome 19 at position 13.3. Adapted from: 
http://ghr. n 1m. n ih.gov /dy nam ic I mages/chromomap/ld Ir .jpeg 
LDLR i expre sed on the cell surface and is an 839 amino acid protein (Brown and 
Gouldstein. 1986). LDLR consists of six different domains and each domain has its 0\\ n 
di tinct function (Heath et ai, 200 1). Each exon of the LDL receptor gene (LDLR) codes 
for a pecific part of the protein. Exon 1 ,  for e ample, codes for the hydrophobic H:!­
terminal signal sequence that directs the nascent receptor chain to the endoplasmic 
reticulum (databa e of FH Mutations). The second domain i the ligand binding domain 
\\hich i located on extracellular side of the cell. The ligand-binding domain is made up 
of seven repeats of 40 amino acids named RI to R7 (Rudenko, et at, 2003). The e 
repeats are homologous to sequence of the protein C9 of the complement cascade 
( udhof et ai, 1985). Each repeat contains six cysteine residues that fonn three disulfide 
bonds. The COOH- terminal end of each repeat contains a negative1 charged triplet, 
SDE. \\ hich is important for ligand binding (Sudhof ef ai, 1985). This domain is coded 
by exons 2-6 (database for FH mutations). The third part of the LDL receptor is the EGF 
precur or gene homology and encode a 400-amino acids sequence that is 33 % identical 
to a portion of the human epidermal growth factor (EGF) precursor gene (Rudenko el 01, 
2003 and Esser, 1988). This region includes three growth factor repeat which are 40-
amino acids cysteine-rich sequences that differ from the cysteine-rich sequences in the 
ligand-binding domain. The two fir t repeats are contiguous and separated from the third 
by a 280-amino acids sequence that contains five copies of a con erved motif (YWTD) 
repeated once each 40-60 amino acids (Rudenko et ai, 2002). This domain is required for 
- 1 0 -
the di 'ociation of lipoprotein from the receptor in the endosome during receptor 
r cycling. It al 0 erve to po ition the ligand binding domain 0 that it can bind LDL on 
til c II urface (Gent et al. 2004). Thi domain i encoded by E on 7 to 14 (database 
for FII mutation ). The fourth region i the Carboh drate chain domain and is encoded 
by :-.on 15. Thi i a 58 amino acid region that contains 1 8  erine and threonine re idue , 
to mo t of \\ hich are attached hort carbohydrate chain in O-linkage (databa e for FH 
mutation and E r. 1 988) .  The fifth part i the transmembrane domain, thi domain is 
located on Exon 16  and the 5' of E, on 1 7 . thi domain consi ts of 24 hydrophobic amino 
acid of the membrane-spanning domain \vhich anchor the LDLR in the lipid bilayer 
(Gent er al. 2004). The ixth part i the Cytoplasmic domain and located on 3' of Exon 
1 7  and Exon 1 8, thi domain encode the 50 amino-acids that make up the cytoplasmic 
domain. Thi domain i important for the localization of the receptor in endocyto is 
(coat d pits) on the cell surface and the internalization of the LDLR into the cytopla m 
(Gent et al. 2004). 
Ligand 
Binding 
Repeats 
1-7 
} EGF-A EGF-B 
} �-Propeller 
} EGF-C 
} Linker 
} Transmembrane 
} Intracellular 
Fig u re 8. LDLR Protein Structure. The diagram shows the different domains of the 
LDLR protein. The ligand binding domain, EGF precursor homology domain, the 0-
linkage domain, the transmembrane domain and the Cytoplasmic domain. 
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1.6. Regulation of LDLR Expression 
LDLR e pre ion i predominantly regulated at the tran criptional level through a 
negative-feedback me hani m b the intracellular chole terol pool (lssandiu et aI, 2004) 
The LDL r eeptor (LDLR) play a pivotal role in the control of plasma cholesterol level . 
LDL-c binds to the LDLR expre d on the urface of hepatocyte and is removed from 
(h circulation by LDLR-mediated endocyto i . Thu . the expre sion Ie el of hepatic 
LDLR i directly influenced by pIa rna LDL-c (I andiu et 01. 2004). This regulation is 
controll d through specific interactions of the sterol-regulator element ( RE-I) of the 
LDLR promoter and a family of SRE-binding proteins, namel ,SREBP-I and SREBP-2 
( 1  andiu et 01,2004). REBP are member of the basic helix-loop-helix leucine zipper 
famil) of tran cription factor . REBPs contain 2 transmembrane domain and are 
local ized to the endopla mic reticulum (ER) after synthesis. [n the inactive state within the 
ER. REBP as ociate with another transmembrane protein SREBP cleavage-acti ating 
protein ( CAP) (Gent et aI, 2004).That provides conditional chaperone activity to the 
REBP. The CAP contain a chole terol-sensing domain that responds to the depletion 
of terol \ ith acti ation of SCAP-SREBP-transporting activity. Under cholesterol­
depleted conditions, CAP tran ports SREBP to the Golgi, where the H�-terminal 
tran cription-acti\ation domain of the SREBP is relea ed from the precursor protein 
through specific proteolytic clea ages. The active form of the SREBP translocates to the 
nucleus, where it binds to its cognate SRE-l site, which activates the transcription of the 
LDLR gene (Gent et 01, 2004; Lopez, 2008). 
p I  REBP 
• • 
/ � 
\ I c,,('ceCA ' 
t 
RE 
Tran. criplion 
--------3 
t 
IRE 
Figu re 9. Promoter region of the LDL receptor gene .. Three direct repeats (Repeat 1. :3 
und 3 )  and 1\\0 TATA-lih.e sequences are identified within the promoter region. The c:is­
CJuil1R element of terol i located on repeat 2, \vhereas the regulator) element for 
c)tokine OM ( IRE) overlap the TATA-like equ nces.Adapted from: Kong el al .. 2005 
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Th LDL receptor i a cell- urfac gly coprotein that i )- nthe ized a an immature 
prot in and proce ed in the olgi apparatu ,\\her the mature fom1 of the LDLR i 
produ ed (Burden el al. 2004).Th function of thi protein i to bind pecifically to the 
LDL particle through the binding with the apolipoprotein B portion in LDL particle . 
The rec ptor-ligand complex i then internalized to the cytoplasm by endocytosi la 
clathrin-coated pit through interaction in 01 ing the LDL receptor adaptor protein, 
LDLR PI (Familial H)p r hole terolemia, 2005). The complex i tran ported ia earl) 
endosome to the late endo omal compartment, where the acidic en ironment of the 
end ome help to di ociate the receptor-ligand complex. The LDL particle i degraded 
in the I)s ol11al compartment while LDLR is rec cled to the membrane (Familial 
By perchol terolemia.2005). 
1 . tH� 
R d�cta�;� \ 
LDL Receptor 
-
Internal Lysosomal �Regulatory LDL B md lng � Izatlon 
...... 
Hydroly I ActIon 
I 
Figu re 10. Summary o f  tbe LDL Patbway. The pathway of LDL in the body LDL­
LDLR complex fom1ation, internalization, en do omal internalization and LDLR 
recycling. Adapted from: Brov. n and Goldstein, 1 979. 
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1. 7. Prevalence and Types of Hypercholesterolemia 
Hy per hole terolem ia i a w orld\" ide ri k factor that cau e CH O, M.  Agan al and 
hi col league in 1 995 found that the prevalence of hypercholesterolem ia in U E 
ati nal v ari from 47.2 - 53% V\o h ich increa e the risk for coronary heart d isea e 
(CH O), becau e h igh level of chole terol in the blood can form plaque inside the arterial 
\\ a l l  , cau ing them to th icken and narrow . Hyperchole terolemia can be dietary 
(em ironmental) or hereditary ( Fam i l ial Hypercholesterolem ia, FH) .Commonly FH 
happen due to the 10 -of-function mutat ions in the low-dens i ty l ipoprote in receptor 
(LDLR) gene or the gene for apol ipoprote in B- 1 00 (APOB). or the proprotein con ertase 
ubt i l i  i nlkexin ty pe 9 ( PC K9) gene, or the LDLRAP I gene or due to other mutat ion in 
t i l l  un ident ified genes (Austian et ai, 2004 and Marais, 2004). Fam i l ial 
H) percholesterolemia is mostly dominantl inherited conditions a ociated v. ith 
premature CHD and my ocardial infarction as mentioned above. The pre alence of FH 
heterozy gou i about 1 :500 in most population and I :  1 000 000 for the homozygous 
(Kankh.onen et al . 2004).  Early d iagnos is of FH i important and al lows people to start 
treatment of hyperchole terolemia to lower their  cholesterol and reduce the risk of 
de eloping CHD. T n  add it ion, knowledge of a genetic predispos ition (see table 2 )  for 
hy perchole terolemia may prov ide powerfu l motivation for l ifestyle changes (Mark er aI, 
2003) .  
--
- -
---- -
- Fam i l ial hyperchole terolem ia LDLR 
- Fami l ial  defective apo B- I 00 (FDB) apo B 
- Autosomal dom inant hypercholesterolem ia (FH3)  l inked to 1 p32 
- Autosomal recess i e hypercholesterolem ia ARH 
- Cholesterol 7 alpha-hydroxylase defic iency CYP7A I 
- Fam i l ia l  s itosterolem ia ABCG 5 and A BCG 8 
- Hypercholesterolemia assoc iated with rare apo E apo E 
Table 2. Monogenic d isorders and  related genes associated with 
h percholestero lemia Adopted from :  Fernando Ci e l ra (2004). Gu idel ines for the 
d iagnosis and management of heterozygous fam i l ial hypercholesterolem ia, 
Atherosclerosis  1 73 55--68. 
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1. 8. Familial Hypercholesterolemia (FH) 
Fami lial hypercholesterolemia (FH) is a serious health problem in most populations 
inc luding Arab and is considered as one of the most common autosomal dominant 
inherited metabolic disea es with an average worldwide prevalence of about 1 in 500 for 
heter zygotes and less frequent for homozygous with pre alence of about one per mil l ion 
a ment ioned abo e (Kankkonen er aI, 2004). FH is characterized by marked elevation of 
serum low-density l ipoprotein cholesterol (LDL-C) levels, deposit of cholesterol in 
several tissues and premature coronary heart disea e (CHD) as well as the presence of 
tendon anthoma, xanthelasma, and premature arcus corneae in the eye (Aalst-Cohen ef 
al, 2006). 
FH can happen due to more than one genetic factor, it can happen due to the loss-of­
function mutations in the low-density l ipoprotein receptor (LDLR) gene or the gene for 
apol ipoprotein B- I 00 (APOB). or the protein convertase subti l isinlkexin type 9 (PCSK9) 
gene, or the LDLRAP I gene or due to mutation in sti l l  unidentified genes (Yuan ef aI, 
2006). The main causes of FH are associated with mutations in the LDLR gene, including 
nonsense. missense, dupl ications and insertions mutations (Chater ef ai, 2006, Lombardi 
f af, 1 995) .  To date there are no molecular data avai lable on tills i l lness in the UAE 
despite c l inical and biochemical data suggesting its significant prevalence in UAE Arab 
populations (Agarwal ef al. 1 995).  
1. 9. Clinical Presentation of FH 
FH patients are characterized by their increased plasma level of total cholesterol 
and LDL-cholesterol ,  which may reach to twofold of the normal level for the 
heterozygous FH in which hypercholesterolemia is present from birth (WHO Report, 
1 997). while CHD may not appear until age 50 in men and at age 60 in women (Marks et 
af, 2003). Tendon xanthoma, xanthelasma, and premature arcus comeae are other 
symptoms present in some individuals with FH (WHO Report, 1 997 and Bhatnagar ef af 
2000). These c linjcal symptoms and their severity depend on the l ifestyle and diet habits 
of each individual (WHO Report, 1 997). 
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Homozygous FH patients have much more severe hypercholesterolemia, with a 
lX t tenfold increa e in total plasma cholesterol and a more than fivefold increase in 
pia rna LDL-chole terol .  Homozygous FH-associated mutations in  LDLR typ ically show 
planar xanthomata by age six,  and may exhibit symptoms of CHD by age 1 0, and, if 
untreated. u ually die of myocardial infarction by age 20 (WHO Report, 1 997). 
1. 10. Diagnosis of FH 
1 . 1 0 . 1 .  C l i n ical d iagnosis 
C linical diagnosis of FH i s  based mainly on the presence of elevated total 
p lasma cholesterol .  There are many symptoms which may help to detect the FH 
patients; UK fol lows specific c l in ical presentation (WHO Report, 1 997) to detect 
the FH patients as follows: 
- Total Cholesterol >6.7 mmolll(260 mgldl)if under 1 6  years old or >7.5 
mmollL(290mgldl) if older than 1 6  years old.  
- Xanthomata in first or second degree relative. 
- Family history of myocardial infarction under age 60 in first degree fami ly 
relative or under 50 in second family relative. 
- Family history of h igh level of cholesterol .  
The diagnostic cut-off points vary depending on age and family history of 
hypercholesterolemia or premature CHD (WHO Report 1 997). Presence of tendon 
xanthomata, xanthelasmata and arcus cornea confirm a diagnosis of FH, but do not 
occur in al l  individuals with FH and may not develop until later in l ife (Goldstein 
and Brown, 1 995) .  
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Fig u re 1 1 . Symptoms of  F H .  Show the symptom of  FH : Xanthclasmata around the 
e c,  T t:ndon xanthomata on the elbow and fingers, and arcus cornea. 
Adopted from:  http://www .scielo.br 
1 . 1 0.2 .  G e n etic  d i agnosis  
Genetic te t ing a l low diagnosis of FH based on 0 A mutation screening 
method at any age and before any c l in ical  symptoms devclop ( WHO Rep 011, 
1 997) .  It is therefore pa11icu1arly valuable for fam i ly  creening, and has been 
ho\.\ n to be ign ificantly more accurate in  detecting affected fami ly  members than 
biochemical te ting ( WHO Report, 1 997) .  
1. 1 1. Treatment of FH 
Treatment of FH is ba ed on depleting the level of l iver cel ls cholestero l ,  which 
acts as a feedback i nh ibitor of LDLR expression. Lower Ie e ls  of cholesterol in the l i ver 
cel l  lead to an increase in  the number of L D L R  molecule expressed on the cel l  urface, 
which impro e p lasma clearance of LDL.  Treatment of FH depends on the se erity of 
FH in  each patient ;  for patients heterozygous for FH i t  varie between dietary restriction 
of chole terol and saturated fat and administration of bile acid sequestrates p l us l i fe style 
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change which require more e ercise. in addition to statins treatments which have proven 
to effectivel lower LDL concentrations in mo t cases of FH by inhibiting the enzyme 
HMG-CoA reductase which catalyzes the rate-l imiting tep in cholesterol biosynthesis 
(Arambepola et aI, 2007 and Neil et al. 2003 ) . Statins may be combined with other 
treatment methods l ike lovastatin, sim a latin or paravastatin, which selectively inhibits 
intest inal absorption of dietary and bil iary cholestero1.These combined treatments show 
effective re ul t  in reducing the LDL level (WHO Report, 1 997). In cases of FH 
homozygote, patient require pheresis treatment in order to clean up their blood from the 
LDL particle plus the previou mentioned treatments (WHO Report, 1 997). 
1. 12. The Genetics of FH 
There i s  more than one gene which may lead to FH, as mentioned above; the main 
mutated genes are l i sted below in more detai ls. 
1 . 1 2 . 1 .  L D L R- M utations 
Over the last 20 years or so, more than 1 600 different mutations on the LDLR 
gene have been reported to cause FH .  Mutations in the LDLR gene have been 
c lassified into five functional groups based on the characteristics of the LDL receptor 
produced (Database for FH Mutations). Those mutations could be homozygous: 
individuals who inherited two copies of the mutated gene are called homozygotes 
individuals with one mutated copy of the gene and one normal copy and are cal led 
heterozygote. Heterozygote FH shows wide ethnic variation frequency. For example in 
the C hristian Lebanese community, FH heterozygotes prevalence is about 1 in 2 70 
individuals (Abdulrahman, et ai. 1 998). 
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Fig u re 1 2 . C lasses of  LDLR m u tat ions L DL-LDLR Cycle showing the five cla e of 
FH-cau ing L D L R  mutat ion : C las I :  The receptor synthesis mutation, Cia s 2 :  
Tran port-Defective mutation, C lass 3 :  Bindi ng-Defective mutation , Clas 4: 
In temal ization- Defective mutation and Class 5: Recycl ing-Defect ive M utation, 
1 . 1 2. 1 . 1  C l a sses of t h e  L D L R  M u tat ions  
The LDLR mutations can be classified into five categories depending on the 
loss-of -function mechanism as shown in F igure 1 2 . Those c lasses of mutations 
are detailed below: 
C l as s  1 :  The N u l l  Al le le  
The expression of the nu l l  a l lele re u l ts  i n  the ab ence of LDL receptor 
synthesis and the cel l  produced no LDLR.  The cause of this type of mutation i a 
deletion of  the promoter and first exon which code for LDLR, and i f  the LDLR is 
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made, it is made incorrect! and immediately sent to the lysosome to be 
de troyed (E ser el ai, 1 9  ) .  
Clas 2: Transport-Defective mutation 
In healthy cells, proteins are made on ribosomes and are sent from the 
Endopla mic Ret iculum (ER) to the Trans-Golgi Network (TGN), while cells that 
e pre s the transport-defective al lele cannot complete th is transport (Yu el al. 
1 996).  TI1 is  i because the ER has a mechanism through which it prevents 
defecti e proteins from being sent to tbe TGN and subsequently to its standard 
destination (Yu el al. 1 996).  When such defective proteins occur, they wil l  
remain in tbe ER in an effort to either repair or recycle them (Hobbs ef ai, 1 986). 
There are two subgroups of Class 2 mutations. 
Class 2A mutations prevent the damaged or mutated LDLR from leaving 
the ER in an attempt to repair the affected protein.  
Class 2B mutat ions release some of the receptors to the cel l  surface, but 
this amount is sign ificantly reduced compared to normal and therefore 
cannot support the full biological function. 
Class 3: Binding-Defective mutation 
Class 3 mutations are similar to c lass 2B, where the receptors reach the 
cell surface but are defective in  its l igand binding ability (Yu ef aZ. 1 996). 
However, class 3 mutations are categorized in that they are sti l l  able to perform 
intracellular transport. This is mostly due to a result of in-frame rearrangements 
in the Cystein-rich repeats of the l igand-binding domain of the LDLR or the 
adjacent growth factor repeats of tbe Epidermal Growth Factor (EGF) precursor 
domain (Goldstein ef ai, 1 979).  Deletions of l igand binding repeats have different 
effects on the abi lity of the receptor to b ind LDL particles. 
Class 4: I n ternalization- Defective m utation 
Although very rare, c lass 4 mutations occur when the receptors are 
distributed over the cel1 surface and are not arranged in coated pits, which prove 
that a single LDLR without coated pits cannot carry LDL into the cell .  This 
provided evidence to scientists that cell surface receptors must cluster in c1athrin-
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coated pit to be able to complete the internal ization process. Like class 2, clas 4 
is di ided into tw ubgroups: 
• Clas 4A deal with a mutation on the cytoplasmic domain alone, while 
• Ctas 4B involve a mutation on the cytoplasmic domain together with the 
adjacent membrane-spanning region (Goldstein el af 1 985). 
In the Arab ethnic mutation FH-Bahrani is al1 example for class 4 mutations 
which have premature stop codons that shorten the protein and alter the abil ity to 
internalize l igand into the cell (Leherman et af. 1 985)  
Class 5 :  Recycl ing-Defective Mutation 
LDLR is  one example of a protein from a c lass of recycling receptors that 
bind to l igands at the surface of a cell, endocytose them in c lathrin-coated pits, 
separate from the l igands in the endosome and are returned to the cell surface 
after recycl ing ( Leherman ef af. 1 985) .  
The recycl ing defective mutation is related to deletion in the gene that 
codes for LDLR in the hepatic cells. In such a mutation where LDLR EGF 
Precursor Homology domain is deleted, the LDL receptor cannot release the LDL 
particles inside the endosomes (Albert, 2001 ). " I ntercel lu lar Dissociation ' that 
happens inside the endosome is go erned by protein pumps within the wall of the 
endosome. These pumps lower the pH of the environment inside the endosome. 
The three cysteine-ricb growth factor areas in LDLR are responsible for the 
acceleration of the acid-dependant l igand binding dissociation and thereby 
faci litate receptor recycl ing (Albert, 200 1 ). In the mutated LDLR, the acidic 
environment of the endosome is  no longer able to separate the LDLR from the 
LDL, as it does for normal proteins (Albert, 200 1 ) . 
The majority of mutations in the LDLR which have been identified to date 
are categorized in class 2 or c lass 3 mutations occurring in the l igand-binding and 
epithelial growth factor precursor regions of the gene (Austin, 2004). 
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Figure 1 3 .  T h e  p e rcen tage of t h e  L D L R  m u tat ion : Show the percentage of the LDLR 
mutation on  each exon and the defect i  e domain from the diagram we  can sec that most 
of the L D L R  mutations Jay in  the L igand binding domain  and the EGF Precursor 
H omology Domain .  
( dapted from Databa e for F H  mutation available on l ine :  www.ue 1 .ae. ukJfh ) 
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Figure 1 4. T h e  p ercentage of  t h e  L D L R  m u tat ion  types : Sbows the perccntage of the 
L D L R  mutation type . Substi tution , deletion, insettion, dupl ication, inscrtion! deletion 
and inv r ion mutation. The 1110 t frequent type of LDLR mutation i the ub t i tution 
mutations. 
( dapted from Databa e for FH mutations avai lable online: www.uel .ac.ukft11 ) .  
1 . 1 2 .2 .  Apolipo p rotein B- I OO gen e  m u t at ions  
ApoB l OO form is the main apoprotein of  the L D L, LDL-LDLR complex 
fonuation i mediated by apolipoprotein B- I 00 ( Apo B- I 00) ,  where los -of­
function mutation in the Apo B- I 00 gene can decrease the efficiency of L D L  
binding to L DL R,  therefore leading t o  increased plasma levels o f  total and LDL­
cholesterol (Innerity e t  ai, 1 987 ) .  The primary structure of the carboxyl-terminal, 
3 0  percent ( 1 45 5  amino acids ) of  human apo-B (apo- B I OO) ,  has becn deduced 
from the nucleotide sequence of complementary DNA. Portions of the protein 
structure that may re late to i ts  receptor binding function and l ipid binding 
properties have been ident ified ( Powe l l  et ai, 1 985) .  The apo-B I OO messenger 
R A i about 1 9  k i lobases in length. TI1e apo-B 1 00 gene is expressed primari ly 
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in the liver and, to a lesser extent, in the small intestine, but in no other t issues. 
The gene for apo-B l 00 i located in the p24 region (near the tip of the short arm) 
of chromosome 2 (Powel l  ef of, 1 985) .  
All FH-associated mutations in Apo B- 1  00 identified to date are clustered 
within a 200-nucleotide region in exon 26 and 29  of APOB gene ( Innerity el 01, 
1 9  7) .  
1 . 1 2 .3 .  L D L RA P I  gene m u ta tions 
The LDLRAP I gene (also known as autosomal recessive 
hypercholesterolemia or ARH)  provides instructions for making a protein that 
helps remove cholesterol from the blood stream (Zuliani  ef aZ, 2003 ) The 
LDLRA P I protein interacts with LDLR. More than 1 0  mutations in the 
LDLRAP I gene have been reported in this gene which causes a form of i nherited 
high cholesterol called autosomal recessive hypercholesterolemia. The 
LDLRA P I protein appears to play a critical role in internalizing the LDL-LDLR 
complex from the cel l surface to the interior of the cell. Once inside the cell, low­
density l ipoproteins are broken down to release cholesterol .  Abnormal ities of th is 
gene are unclear, but it seems to play a role in the relation between the LDL 
receptor and c lathrin-coated pits. Patients with autosomal recessIve 
hypercholesterolemia tend to have more severe disease than LDLR-heterozygotes 
but less than LDLR-Homozygotes (Zul iani el al. , 2003 and Soutar ef aI, 2003 ) 
1 . 1 2 .4 .  P C S K9 (proprote i n  convertase s ubtilisinJkexin type 9) 
M u tations 
Proprotein convertase subti l isin kexin 9 ( PCSK9) is a member of the 
subti l i sin serine protease family with an important role in cholesterol metabolism 
(Kara ef af. 2005 ) .The PCSK9 protein serves to control the number of low­
density l ipoprotein receptors expressed on the cell surface. Studies suggest that 
the PCSK9 protein helps control blood cholesterol levels by breaking down low­
density l ipoprotein receptors before they reach the cell surface. This means that 
gain of function mutation in this gene wil l  prevent the LDLR to reach to the cell 
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urface and thereD re no LDL particle can be internal ized into the cell and , 
pia rna LDL level wil l  stay elevated. Mutations in this gene are considered as 
auto omal dominantl inherited disorders and are so called. (Lambert ef at. , 2008; 
Lopez, 2008). 
1. 13. Genetic Testing/or FH 
Hypercholesterolemia evaluation can help in detecting patients with FH at any age. 
Such early detection is critical, since prevention or treatment of hypercholesterolemia 
may pre ent or delay the onset of eHD (WHO Report, 1 997). Height level of total 
chole terol in young person can be a strong indication of mutation leading for FH. For 
genetic testing, D A for sequencing can be obtained from leukocytes present in a small 
blood sample. The entire coding sequence of the genes that cause FH are ampl ified 
through a polymerase chain reaction (peR), peR products then are fully sequenced. 
Sequencing results are interpreted for identifying the mutations that cause FH (WHO 
Report, 1 997). 
1. 14. FH in Arab PopUlations 
FH is  a c lassic disease that has been extensively studied for several decades. 
M utations are sti l l  being discovered and tested to help scientists classify all types of 
mutations that can cause FH.  Many Arab countries which have been screened for 
mutation for Fami l ial Hypercholesterolemia shows a h igh prevalence of the mutation in 
the Arab population specially on the LDLR gene. Not all  Arab countries have yet been 
screened for the mutation so, the molecular information about the Arab world is still not 
yet ful l  known, M any studies shows the presence of the Arab mutation in non Arab 
countries in patients w ith Arab ancestry in non Arab countries; specially the countries 
with large Arab population immigrants, such as North American and Western European 
countries. Mutations in genes underlying FH in Arab countries have been reported in the 
l i terature as summarized in figure ( 1 5) and table 3 and reviewed in more detai ls below: 
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Fig u re 1 5. shows t h e  reported L D L R  m u tat ion i n  the A rab co u n tries 
Map Adapted from W WW . ArabBay.eom 
Algeria. 
Several L D L R  m utations are found in the Algerian population; the database for FH 
mutation I i  t fi ve di fferent mutation in  Algerians; ( F  Q 1 2) :del C a t  97 ,  FH A lgeria-4: 
del G at 99. F H  A lgeria-3 (T4 1 3 K ) :C>A at 1 30 1 ,  FH Algeria-2( A4 1 0T ) :G>A at 1 29 1 ,  
F H  A lgeria- l tOsaka ( E387K) : G>A at 1 222 ( 1 5 ) . In  addition, FH A lgeria ( LD LR, Ala 
4 1 0  TI1r) i found in  Algerian patient , a GCT- to- ACT change .  
Bahrain. 
ill a Bahraini  patient with F H ,  Lehnnan et a l .  ( 1 985 )  found a change in  the tryptophan-
792 codon to a top codon as the basis of  th i variant ( W792 X ) ;  thi mutation is cal led 
F H  Bahrain .Truncation of the cytoplasmic domain of the L D L R  protein results in 
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defective internal ization. Recurrence of this mutation wa observed by Loux et al .  ( 1 99 1 )  
ill the course of a survey of 1 39 unrelated French FH subjects (LDLR: OMIM ). 
Iraq. 
Databa e for FH mutation reported only two mutations on the LDLR gene in the Iraqi 
populat ion. C20 1 G: T>G at 664 and C28 1 W: C>G at 906. 
Ku wait 
A study done by Lombardi and others in  1 995 showed a novel missense mutation in 
Exon 1 0  named V502M (FH-Kuwait) where a substitution of G > A at 1 567 lead to the 
Val to Met 502 substitution . According to the database of OMIM the same mutation is 
l i sted GTG- to - A TG mutation is responsible for this variant. 
Lebanon. 
Lebanon l ike most of the Arabic countries has high incidence of genetic diseases due to 
mosaic different ethnic origins and high rate of consanguineous marriages (Kaloustian et 
01. , 2005 ) .  Lehrman and his colleagues found that the homozygous LDLR mutation 
present in high frequency in Lebanon is about 1 0  times higher than the other parts of the 
world ( Lehrman et al. , 1 987) .  OMIM database reported that Lebanon is the first country 
to establ ish the existence of homozygous FH. The most abundant mutation in Lebanon is 
FH Lebanese [ LDLR. Cys 660 Ter] which occurs on exon 1 4  which has been identified in 
many Lebanese pat ients in different studies. Call is and other in  1 998 reported the same 
mutation on the LDL receptor gene on exon 1 4  in two Lebanese patients. The mutation 
designation is C660X which results from nucleotide changes T>C at 2043 on the LDLR 
gene. This mutation is named (Lebanese al lele mutation) (Leitersdorf et al., 1 99 1 ) .  This 
mutation is found in Lebanese and Syrian patients and is characterized by producing 
mutant LDL receptor, lacking three domains; the c luster O-Iinked carbohydrates region, 
the membrane- spanning region and the cytoplasmic tail (Leherman et at. , 1 987) .  This 
mutation occurred due to single nucleotide substitution which resulted in a premature 
term ination codon at amino acid 660, el iminating 1 80 residues from the protein 
( Leherman et aZ. , 1 987) .  Specific mutations are present in high frequencies in certain 
population (Alberto eta1 . 1 999), for example some Arab ethnic mutations occurred in non 
Arabic countries with Arab ancestry population l ike Brazi l ,  where C660X ( Lebanese 
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mutation) was found in Brazil ian patients (Kerbhof, 2003). This was identified in a study 
done by Alberto and others in 1 999 when they found that the Lebanese allele in the 
Middle Ea t population (Alberto ef al. 1 999). In this study they determined the molecular 
basis of FH in 59 patients from 3 1  unrelated Brazi l ian fami l ies. All patients were 
creened for the Lebanese mutation which was detected in 9 of the 3 1  fami l ies, and 
alway a so iated with Arab ancestry. Two different LDLR gene haplotypes were 
demon trated in association with the Lebanese mutation (Alberto ef al. 1 999).The results 
suggest that the Lebanese mutation is considered as a cause of FH in Brazil and by 
analogy the same feature may be expected in  other countries with a large Arab 
population such as ortb American and Western European countries (Alberto ef 
al. 1 999). 
Morocco. 
The fol lowing mutations were identified by Chater and others (2006) in Moroccans 
nonsense mutation (C25X) in Exon 2, Splice mutation (IVS3+5 G >T) in Intron 3 and 
M issense mutation (D I 5 1 N) in Exon 4, Exon 1 0  (A480E) and Exon 1 2  (D558A) in the 
LDLR gene, The R3500Q and R35 1  mutation of the apoB gene were absent. Another 
paper from Messal and others in 2003, showed that 27 patients with FH from 8 unrelated 
fami lies carried some LDL receptor gene mutation but none of them carried apoB gene 
mutations in Morocco. They found 7 mutat ions in LDL receptor gene including 5 
m issense mutation on Exon 4, 6 8 and 1 4  ( C 1 l 3R, G266C, A370T, P664L, C690s) and 
two large deletion mutations( FH- Morocco- l and FH- Morocco-2) .  Another Nonsense­
mutation (E207X FH Morocco): G>T at 682 mutation on exon 4 has been reported by 
Zakharova and his colleagues in 2005 . 
Palestine. 
In a study done by Oppenheim et al .  ( 1 99 1 )  they found the 'Lebanese' allele in correlation 
with hypercholesterolemia in 5 Christian-Arab kindreds in Israel ( LDLR: OMlM). 
Database of FH mutations reported two Palestinian mutations; del G at 554 (FsG 1 65 )  and 
G>A at 622(EI 87K, FH Jerusalem), which have also been reported by Reshef and others 
in 1 996 in the Arab Moslem in Israel. FH Druze (Y 1 67X) [LDLR, Tyr 1 67Ter], is another 
mutation found in famil ies from 2 distinct Druze vil lages from the Golan Heights in 
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northern I rae!. The mutation was detected on exon 4, which encodes for the fourth repeat 
of the binding domain of the mature receptor, where TAC-to-TAG substitution in codon 
1 67 ,  changes the ense from tyrosine to stop codon (LDLR: OMIM ) .  FH aples [LDLR. 
Gly 544 Val ] ,  LDLR mutation GGC to GTC causes a change from Gly 544 to Val 
mutation (LDLR: OMIM).  
Syria. 
OMIM and Database for FH Mutations reported different type of FH mutation in Syria on 
the LDLR gene, (C 1 63R) :  T>C at 550, (C255Y):  G>A at 827, (FsA370): del I at 1 1 72, 
FH Lebanese (C660X):C>A at 2043, (C646R): T>C at 1 999, FH J .D Bari!Potenza 
(y 07C): A>G at 2483 and FH Picardie-3 (G322S):  G>A at 1 027. 
Tunisia. 
Many studies ha e been done to find out the genetic causes of FH in Tunisia.  One of 
these studies was done by S l imane and others (2002) .  The objective of his study was to 
characterize the LDL receptor (LDL-R) gene mutations causing familial 
hypercbolesterolemia (FH) in central and southern Tunisia in order to investigate the 
influence of potential modifier alleles on pbenotypic expression of FH. They analyzed 
The LDLR gene and apoE gene and two novel missense mutations were identified in the 
LDLR gene and two missense mutations in the LDL receptor gene were identified. The 
first mutation is a novel mutation replacing G with C at nucleotide 443 (443 G>C) 
causing a substitution of cysteine for serine at codon 1 27 in exon 4. This mutation is 
named C I 27S or FH-Kairouan (Sl imane et aI, 2002). The second mutation replaces G 
with A at nucleotide 796 (796 G>A) and causes a substitution of aspartic acid for 
asparagine at codon 245 in exon 5 .  This  mutation, named D245N or (FH-Tozeur) and 
involving a CpG d inucleotide and located on exon 5, has been reported in a Dutch patient 
and results in a h ighly conserved residue located at the C-terminal end in tbe sixtb of tbe 
even cystein ricb repeats that form the binding site for apoB. The C 1 27S mutation in 
exon 4, designated FH-Kairouan, changed a highly conserved cysteine in  the fourth of tbe 
seven tandem cysteine ricb repeats involved in the structure of tbe l igand binding domain 
(S limane et aI, 2002). Most missense mutations located in this region bave been reported 
to produce a class 1 (null al lele) or a c lass 2 (transport defective) type of defect (Sl imane 
et aI, 2002). Therefore, these mutations were found to be responsible for a profound 
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alteration in LDL-R function and an FH phenotype in this Tunisian population (Sl imane 
ef al 2002) .  
Another study done by S limane (200 I)  in Tunisia identified a novel complex frame shift 
mutation in exon 1 0  nucleotides 1 477-1 479 (TCT) at Serine 472 were replaced by an 
insertion of even nucleotides (AGAGACA), producing a premature termination codon 
43 amino acids down tream. This mutation (FH Soua si)  was a deletion : insertion type 
mutat ion in exon 1 0  in which the codon Serine 472 (TCT) was deleted and 7 bp 
(AG GACA) were in erted. This alteration caused a frame shift mutation introducing 43 
new amino-acids and a premature TGA-Stop codon at residue 5 1 4  within the epidermal 
growth-factor precursor homology domain (Shmane ef aI, 200 1 ) .The database for FH 
mutations l isted the fol lowing mutation in  Tunisia FsV477: del 3, in 7 at 1 493, FH Tunis: 
G>A at 1 845+ 1 and FH Avel l ino-2/ Tunis :  G>A at 1 846- l .  
UA.E. 
M. Agarwal and his colleagues 1D 1 995 found that the prevalence of 
hypercholesterolemia in  UAE Nationals varies from 47.2 - 53% which increase the risk 
for coronary heart disease (CHD) however, there are no molecular data available on this 
i l lness in  the UAE despite c l inical and biochemical data suggesting its significant 
prevalence in Arab populations. Frossard and Lestringant ( 1 999) did a study on UAE 
nationals from Abu Dhabi Emirate using a polymerase chain reaction-based assay to 
investigate the al1ele and genotype frequency distributions of the alleles of a variable 
region located in the 3' of the human apolipoprotein B (apoB) gene. The analysis of DNA 
samples of 367 unrelated UAE nationals (20 1 males and 1 66 females) revealed the 
presence of 1 8  different alleles, ranging from 2 1  to 55 repeats. Frossard et at. ( 1 995) 
analyzed a random sample of 1 0 1  nationals from the United Arab Emirates for the VNTR 
located in  the 3' region of the human ApoB gene. A total of 1 1  alleles (33 , 35 37, 39, 4 1 ,  
43 . 45 , 47, 49, 5 1 ,  and 5 3  repeats) were observed in the general population. 0 mutation 
screening has been carried out on this gene (Tadmouri, 2004) .  
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764 FH Tunis  Tunisian 1 45-+ 1 donor 
del 3, in  7 at 
549 F V477 EGF spacer AGAGACA, Tunisian 
1 493 
>48aa-term 
G>A at I FH A vcl l ino-
1 74 Tunisian 
acceptor 21 Tun i 
6 1 9  G> 27 C255Y repeat 7 Syrian 
6 1  dd 1 at 1 1 72 F A 3 70 repeat B Syrian 
576 T>C at 1 999 C646R repeat C Syrian 
467 T>C at 550  C 1 63 R  repeat 4 S yrian 
FH J . D-
1 02 A>G at 24 3 Y807C CT Syrian 
BarilPotenza 
92 C>A at 20-B C660X repeat C F H  Lebanese Syrian 
FH Pieardie-
5 6  G>A a t  1 02 7  G322S repeat A Syrian 
3 
Tcml after 
649 del G at 554 F G 1 65 repeat 4 Palestin ian 
1 9aa 
29  G>A at 622 E 1 8 7 K  repeat 5 FH JelUsalem Palest in ian 
283  G>T at 9 1  E I OX repeat 1 Moroccan 
3 7  G>T a t  682 E 207X repeat 5 F H  Morocco Moroccan 
92 C>A at 2043 C660X repeat C F H  Lebanese Lebanese 
F H  
7 5  G>A a t  1 5 67 V502M EGF Spacer KuwaitlBari- Kuwaiti 
2 
676 T>G at 664 C20 l G  repeat 5 I raqi 
409 C>G at 906 C28 1 W  repeat 7 I raqi 
26  C>G at 564 Y 1 67X repeat 4 F H  Dn.lZe Druze 
99 G>A at 2439 W792X CT FH Bahrain Bahraini  
- 3 1  -
252 
68 
67 
65 
6 
I del at 97 FsQ 1 2  repeat 1 Algerian 
C>A at l 30 1  T4 l 3K EGF pacer FH Algeria-3 Algerian 
G>A at 1 29 1  4 1 0T EGF spacer FH Algeria-2 Algerian 
FH Algeria-
G> at 1 222 E387K EGF spacer Algerian 
1 I0saka 
I del G at 99 FsQ 1 2  repeat 1 FH Algeria-4 Term at 204 Algerian 
Table 3. List of Arab LDLR Mutation according to ( Database for FH Mutations)  
h ttp.www.ucl .ac.uklfb 
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1. 15. Model system for phenotypic characterization of LDLR mutations 
and cellular trafficking of LDLR 
LDLR is regulatory protein for LDL homeostasis in the body. ewly transcribed LDLR 
mRNA reaches the endoplasmic reticulum for modification, then transported to Golgi 
apparatus where the carbohydrate side chains are modified, the mature LDLR is 
transported to the cell surface where it clusters in clathrin-coated pits, where it can bind to 
the LDL partic les (Ranbeim et aI, 2006) .  Correct folding of nascent polypeptide chains 
within the endoplasmic reticulum (ER) is critical for function, assembly into multi­
subunit complexes and trafficking through the exocytic pathway for secretory and cell 
surface proteins. This process i s  rather inefficient and a substantial proportion of nascent 
polypeptides are rejected by the stringent ER qual ity control machinery and targeted for 
degradation by the ubiquitinJproteasome systems (McCracken and Brodsky, 2003; Chen 
et a l . ,  2005;  Al i  et aI . ,  2007).  In some cases only a minor fraction of nascent chains are 
correctly folded and the smallest alteration to polypeptide primary structure ( i .e .  point 
mutation) can result in  the complete loss-of-function with inherent pathological 
consequences. The group of human genetic d iseases associated with ER retention and 
degradation of the mutated proteins have been named ERAD (Endoplasmic Reticulum 
Associated protein Degradation) d iseases and include cystic fibrosis, fami lial 
hypercholesterolemia and emphysema (Aridor and Hannan, 2000, 2002; Welch, 2004, 
McCracken and Brodsky, 2003 ; Chen et a I . ,  2005 ) .  Some fami l ial hypercholesterolemia 
causing mutations have been shown to be retained in the ER (Brown et al . ,  200 1 ;  Li et aI., 
2004, Ranheim et aI, 2006). Escaping ER retent ion has been shown to be a potential 
target for some ERAD diseases ( Romisch 2004; Cohen and Kelly, 2004) .  For example, 
in  cystic fibrosis  the mutated proteins can be fully functional if they escape ERAD and 
reach their normal location on the plasma membrane of the cell (Denning et al., 1 992 
Brown et al . ,  1 996; Zhang et al .  2003 ) .  Therefore, the ability to manipulate ERAD to 
a l low more folding to take p lace in the ER andlor increase the efficiency of exit of 
partially m isfolded, but otherwise perfectly functional proteins out of the ER may restore 
function at the cellular level and thus achieve a therapeutic advantage. 
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1. 16  Rationale and Objectives of the study 
Cardiovascular di ea es inflict beavy economical and social cost on most Arab 
populations and contribute significantly to their morbidity and mortality rates. Fami l ial 
hypercholesterolemia (FH) is an autosomal dominant inherited disease with 1 00% 
penetrance affecting 1 in 500 people in most populations and therefore is a significant risk 
factor for tbe development of serious cardiovascular disease (Neil et al. , 2004) .  Prolonged 
hypercholesterolemia ( increased cholesterol in the blood) may lead to the formation of 
tendon xanthomas, xanthelasmata and arcus cornea (Goldstein et al., 200 1 ). More 
significantly, high cholesterol levels in the blood usually lead to excessive deposition of 
cholesterol in  the arterial wall leading to atherosclerosis and cardiovascular disease 
(Goldstein ef ai, 200 1 ;  Austin et al. , 2004a). At least 50% of men and 20% of women 
with FH experience serious coronary artery d isease, which may inc lude myocardial 
infarction and death, by the age of 50. The primary defect in FH patients are mutations in 
the LDL-receptor (LDLR) responsible for c learing LDL-cholesterol from the blood by 
intracel lular endocytosis and degradation of this complex ( Hobbs et al. , 1 992). Thus far, 
over 1 600 different mutations in LDLR gene have been shown to cause FH in various 
populations but only a handful of those mutations have been described in Arab patients 
(Goldstein et al. , 200 1 and bttp .www.ucl .ac .ukJfh). 10 addition, the array of mutations 
varies considerably between the various ethnic groups and populations. For example, the 
C660X nonsense mutation in LDLR gene is common in Lebanon or people of Lebanese 
descent but rarely present in other ethnic groups (Callis et ai. ,  1 998; Alberto et aI. , 1 999). 
The second major gene responsible for FH is Apolipoprotein B with about 1 0% of FH 
cases (Austin et al.,  2004b) .  
o molecular genetic studies have been carried out in  the UAE on FH despite 
strong evidence on the prevalence of hypercholesterolemia in its Arab populations 
(Agarwal et ai, 1 995) .  The vast majority of FH patients are not aware of their i l lness and 
therefore early diagnosis is crucial for successful medical intervention to reduce the risk 
of developing serious coronary heart disease and early death . Crucially, the adverse 
effects of FH can be prevented by medical intervention including administering statins 
and making l ife style changes. The WHO strongly recommends such early diagnosis 
(WHO 1 998) and most developed countries including Hol land and the UK have FH 
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creening programs and a reg; try for FH patients (Fouchier ef af.,  2005 ; Humphries et al., 
2006). 
According to 2004 e timates, AE population was around 4.3 mil l ions, including 
about 3 mi l l ion expatriates. UAB has one of the most diverse populations in the Middle 
East, con i ting of the native Emirati ( 1 9%), other Arab and Iranian (23%), South Asian 
(500 0) , and remaining 8% being the Westerners and East Asians. Although UAB 
nationals population is a small population, it consists of many different ethnic 
backgrounds from Yemen, Oman, Egypt, Iraq, KSA, Iran, Baluchistan and India. 
Modern civi l ization in the country and the change from the desert life to this 
lUXury type of l ife lead to the occurrence of new diseases, which was not found before. 
Obesity hypercholesterolemia, and the coronary heart diseases among the population 
occur a con equences of lack of exercising and the unbalanced type of food. 
Obj ectives 
Due to the above l isted facts about the UAE population we aimed to identify 
individuals and fami lies from the UAE suspected with famil ial hypercholesterolemia and 
to identify the molecular defects (mutations in LDLR or Apol ipoprotein B genes) in the 
candidate fami l ies. The importance of this study is to increase the awareness about this 
disease among the population and its consequences if there are genetic causes detected in 
the candidate fami l ies. 
There are no molecular data about this i l lness in the UAB population and once any 
molecular defects are found a pilot registry for these fami l ies can be started and the 
health authority encouraged to work on starting lipid c linics which look after the 
identified patients and patients with other lipid problems. FH is considered as the most 
important risk factor for CHD, which can be preventable if diagnosed in early l ife. DNA 
sequencing method can help in detecting the affected patient with FH regardless of their 
age, rather than using the conventional biochemical and serological tests. 
Increasing the awareness of FH among the population wil l  help to prevent the 
development of CHD and reduce the morbidity due to this condition . Our objectives 
from this  work can be summarized in the fol lowing points; 
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( i )  Review the records and family history of individuals and fami l ies suspected with 
FH and recruit them for the study. 
( i i )  Col lect blood samples from the suspected patients and carry out D A sequencing 
for the exons of the LDLR gene and exon 26 and 29 of the Apo B 100 gene. 
( i i i )  Identif the type of the mutation of LDLR and ApoB l OO FH-causing mutations 
among UAE hypercholesterolemic subjects and establ ish a new data base for the 
molecular defects on th is two gene in the UAE population . 
( iv) Confmn the pathogeniciy of any identified mutation by performing cellular and 
biochemical assays. 
(\') Recording any mutation on the LDLR and tbe Apo B 1 00 gens by starting a pi lot 
registry for each patient and encourage the health authority to start screening 
program for the FH and etting up new l ipid c l inics.  
(vi) We aim to increase the weariness in the population about the disease and the 
importance of following health l ife style and d iet. 
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CHAPTER II  
MATERIALS AND 
METHODS 
- 37 -
2 .  M aterials  and M ethod 
2. 1. . Subjects and Materials 
Study Subject and Consent 
The study was approved by the eth ics committee of Tawam Hospital and the Faculty 
of Medic ine and Health Science of UAE Uni ersity. Blood samples were collected 
from patients of Tawam and AI-Mafraq Hospitals, consent was taken from them 
orall  (appendix n, amount of 5ml was collected in EDTA tubes. Lipid profiles and 
medical records were provided from the hospital for the needed patients. 
O.SM ED TA 
1 6 . 1 2  EDTA (BDH, UK) was dissolved in 1 l i tre of deionized steri le water and pH 
was adjusted to 8. 
Tris-Boric Acid-ED T A buffer (TBE) 
l OX of TBE was prepared by dissolving 1 08g of Tris-Base (S IGMA, USA), 55g of 
Boric Acid ( SIGMA, UAS) and 40 ml of O.5M of EDT A at (pH8.0) The volume was 
brought to 1 l i tre by deionized sterile water. 
Phosphate Buffered Saline (PBS) 
l OX Phosphate Buffered Saline (PBS) was prepared by dissolving 76.50g of NaCI 
and 7 .24g of a�H P04 in dist i l led water. PH was adjusted to 7 .4 and volume 
completed to 1 l i ter with dist i l led water and stored at cold room. 
DEMEM Medium 
DMEM (INVITROGE , UK) was suppl ied with 1 0% FCS (HigeClone, USA), 1 % 
PenStrep ( INVITROGEN, UK) and 0 .5 % gentamycin antibiotic ( INVITROGEN, 
UK). 
Primer Design and Sequence 
Primers were designed for 1 8  LDLR Exons and two of Apo B l OO (26 & 29) exons 
using primer3 web site: (http://frodo.wi.mit.edul) 
- 3 8  -
LDLR I F  GCTCTTC C GGAGAC 
LDLRx l R  GTGCC TT CCCC CAAGTC 
LD LRx2F G CTGTTCCTGATCGG TG 
LDLRx_R GAATCGTGTCACAG 
LDLRx3F  CTTG ACCCCTGACCTCAC 
L D L R. 3 R  GGTATGAGCCCCCAAGAGA 
LDL Rx4F C GTGGTTCAGAGTCC TGG 
L D L RxAR GTTGGAAATCCACTTCGGCAC 
LDL Rx5F AAGCAATCCTCCTGCCTTGG 
LDLRx5R AAGTCACTTGCCCACAGACG 
LDL Rx6F GAATCCATTTGCATGCGTTC 
L D LRx6R CGTGCGAG ACTGTCTCAAAATG 
L D LRx7F TGGAGGTTGTAATGAGCCAAGG 
L DLRx7R ACCCTCCTAACTGCTTTCAAGC 
L D L Rx8F G ATGACACCTGGCTGTTTC 
L DLR x8R  CAAGCCCAAGTCCTAACAG 
L D L Rx9 1 0F GGGAGGCACTCTTGGTTC 
L D L Rx9 1 0R GGTCAGGCTGGTCTTGATG 
L D L Rx I I F  GCCACATTTGGAGTTTGGGGTTC 
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LDLRx l l R  TC GGGAGCAGCTTGGGCTTG 
LDLRx 1 2F GGTCTTCCTGCCCGGAGCA 
LDLRx 1 2R GACCTCCTCCTAGTCACAACC 
LDLRx 1 3 1 4F GTGTCTCATCCCAGTGTTTA 
LDLRx 1 3 1 4R CATTTGACAGATGAGCAGAG 
LDLRx 1 5F CTCACTCAAGAGATCCTCCTGCC 
LDLRx 1 5R CAAGGGAGTGAGGACGACA 
LDLRx 1 6F AAGTGTCCAGGGAGATGTGC 
LDLRx 1 6R GTGATAAAGGACACCAGTGG 
LDLRx 1 7F CAGGCCGCAAGGCGATCTCTAAAC 
LDLRx 1 7R CAGCTGGGAGGGGGCCGCCATG 
LDLRx 1 8F CAGGAGGTGAGAAGTAGGTGG 
LDLRx 1 8R ACAAAGCTCTGGCAGGCAATG 
ApoB26F TACTGTCTCTTCCTCCATGG 
ApoB26R GTCAGGGAAATCATGGAAGG 
ApoB29F CCAAGATGAGATCAACACAATC 
ApoB29R AACTTGACTTGAGAGTTGGG 
Table 4 .  Primers seq uence of the LDLR gene Exons and Exons 26, 29 of the Apo B I OO 
gene 
- 40 -
Site-Directed ,tllItagene i Primer 
1 utant primer were de igned a fol low : 
FOffi ard primer: 5 -tgcgaagatggcttggatgagtggecg-3 ' 
Rever e primer: 3 ' - cggccactcatccaagceatcttcgca-5 ' 
0283 Forw ard primer: 5 ' - getagagaetgccggaactggteagatgaa -3 '  
R er c pnmer: 3 '  - tteatctgaecagttccggcagtctctagc -5 
50_M Forward primer: 5 ' - ccaagggccatcgtgatggatcctgttcat -3 ' 
Re ersc primer: 3 '  - atgaacaggatccatcacgatggcccttgg -5 '  
G525 1 FOffi ard primer: 5 ' - atcaagaaaggggacctgaatggtgtg -3 ' 
Rever e primer: 3 '  - eacaccattcaggtcccctttcttgat -5 ' 
C660S Forward primer: 5 ' - ggetgecagtatctgtccctccctgccccg -3 ' 
Re crse primer: 3 '  -cggggcagggagggacagatactggcagcc -5 ' 
P664L Forward primer: 5' - tgcctccctgccctgcagatcaacecc -3 ' 
Reverse pri mer: 3 '  - ggggttgatctgcagggcagggaggca -5 ' 
Table  5. M u tant  p rime rs of the  designed m u tat ion 
DNA Qunatitation 
o A Quantitat ion was carried out us ing NanoDrop Spectrophotometer NO- I 000 
using TE buffer a b lank. 
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2.2 . .  Method 
Genomic DNA Extraction from Blood amples 
enomic D A was e tracted by using FlexiGene Kit (QIAGEN.UAS), a volume 
of 3 ml of blood was added to 1 5ml falcon tube, 7 .5  ml of G 1 Buffer was added and 
mixed by in erting the tube 5 t imes. Then tube was centrifuged for 5 min at 2000g 
( IEC Centra M P4R, USA). The supernatant was di carded and 1 .5 ml of G2 buffer 
wa added to the pellet, the tube then closed and vortexed immediately unti l  the pel let 
was completely homogenized and incubated for 1 0  min at water bath of 65°C.  After 
incubation 1 .5ml of Isopropanol (S igma, USA) was added and m ixed thoroughly by 
inver ion unt i l  the D A precipitate become visible as threads or a clump. The thread 
was extracted in 1 .5 ml tube and eluted by 1 00Jl I  of FG3 Buffer. 
Polymerase Chain Reaction (PCR) 
A volume of 25 Jl I of PCR was prepared for each sample and amount of 1 JlI of 
D A was used. The reaction mix  was prepared by using (QIAGEN.USA) kit 2.5 Jl l 
l OX buffer, S Jl I Q buffer, 0. 1 25 Jl I Taq (QIAGEN, USA), dNTPs( QIAGEN.USA), 
G ibco Water , and 0.5 JlI of Forward and Reveres primers (metabion, USA ) .  The 
thermal cycler (Verit i  96 wel l ,  Appl ied B iosystems) was TUn on a Protocol of 94°C for 
- m in  denaturation 95°C for 1 m in,  59 °C anneal ing for 1 min,  extinction noc for 1 .5 
m in  for 40 cycles and 1 0  min of noC extra extension and 4 °C overnight. 
Agarose GeL Electrophoresis 
1 .5% of ultra Pure Agarose (GIBCO BRL, Scotland) was used to separate and 
v isualize the PCR products. 1 .5 mg Agarose were d issolved in 1 00 ml of TBE buffer 
and boiled using M icrowave (Phi l ips, Sweden) .  5 Jll of Ethidium bromide was added 
to the agarose after cool ing add the m ixture was poured i nto the gel casting system. 
Exo-SAP cleaning for PCR Product. 
5 Jl l of the PCR product for each sample was treated with 1 JlI of ExoSap-IT 
enzyme (USB 7820 1 ) and incubated at 37°C for 30 min and fol lowed by denaturation 
of the enzymes at 80°C for 1 5  min. 
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DNA Sequencing 
ExoSap treated samples were ent in itial ly to Macrogen ( www .macrogen.com. South 
Korea) for sequencing. Subsequent ly after the purchase of ABI DNA Analyzer by the 
faculty of Medicine and Health Sciences, sequencing was carried out in-house. 
DNA Sequencing Data A nalysis 
Sequence was a l igned with the wild type of the LDLR sequence adopted from 
HUMAN GE OME BROWSER web site (http://genome.ucsc.edu/). and aligned 
using CalustalW website (http://\vww.ebi.ac .uklTools/clustalw2/index.html?)  
equencing tools.  
Site-Directed Mutagenesis 
Mutant primers were designed for the fol lowing mutat ions: (P664L, C646R, 
G525D, V502M ,  D283 , S 1 56L, E207Q, C88F E80K) in the LDLR gene. 
Bacterial trails/ormation 
Competent ce l l s  were thawed on ice, amount of 1 00 II I of competent cel l  E. coli 
(Ma" Efficiency DH5a , Invitrogen, USA) were added to plasmid DNA and mixed 
wel l  by tapping with fInger and incubated on ice for 20 min .  The mix was then 
incubated in 42°C water bath for heat shock for 2 min after that mix were incubated 
on ice for 2 min.  LB broth was prepared and autoclaved, the mix added to the LB 
Broth and incubated with sbaking at 37°C for 45 min.  200 III of tbe cells were plated 
on LB-Kanamycin  plates and incubated overnight at 37°C. On the fol lowing day, 
colonies were picked up grown i n  LB-kanamycin media and plasmid DNA was 
i solated and screened for the mutation. 
Plasmid DNA Extraction (QIAprep Miniprep, USA 2006) 
P lated cells were suspended in 250)..1.1 of Buffer P I .  250)..1. 1 of Buffer P2 were added 
and mix thoroughly  by inverting the tube 4 times, Then 350)..1. 1 of Buffer P3 were 
added and mixed immediately by inverting the tube 4 times. Tbe tubes then 
centrifuged at 1 3 .000 rpm (- 1 7 .900xg). The supernatant was applied to the QIAprep 
spin colum and centrifuged for 30second. The column then was washed by adding 
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0.75 ml of Buffer PE and centrifuged for 30seconds. Columns were transferred to 1 .5 
ml m Icro centrifuge tube and D A eluted using 50)11  of Buffer EB. 
Cell Culture 
HeLa cel ls were cultured in Dulbecco's modified Eagle's medium ( Invitrogen, UK) 
upplemented with 1 0% fetal calf serum, 2 mM L-glutamine and 1 00 U/ml 
penic i l l iI L  streptomycin at 37°C with 1 0% C02 incubator (FORMA Scientific Inc. 
USA). For transfection, cel ls were grown in a 24 well tissue culture plate. 
Tran fection was perfonned using the l iposomal transfection reagent FUGENE 6 
( Roche Diagnostics), according to the manufacturer's instructions. 
Cell Tran ifection 
We used FUGENE 6 Transfection protocol ( Roche Diagnostics, USA) for 
transfect ion of HeLa cells by pipetting 94 )11 of OPTIMEM ( Invitrogen, UK) media 
into a sterile eppendorf tube and adding 2 )11 of FUGENE 6 to the same tube directly 
into the media and mixing by fl icking the tube several time then left at room 
temperature for 5minutes. After that 1 )11 of Miniprep plasmid DNA was added to the 
mix and m ixed by fl icking the tube. The mix was then incubated at room temperature 
for 1 5-25 m inutes after which the mix was spun down briefly to allow the contents to 
be collected at the bottom of the tube. The transfection m ixture was directly added to 
the cells without removing the medium then cells were returned to the incubator and 
left for expression t ime (24-48 hours). 
Immullochemistry 
Rabbit anti-calnexin polyc lonal antibodies were purchased from StressGen 
Biotechnologies, USA and used dilution 1 : 500);  Alexa Fluor 568-goat anti-rabbit IgG 
from Molecular Probes were used at di lution 1 : 200. For immunofluorescence, cover 
slip-grown HeLa cells were washed with phosphate-buffered sal ine ( PBS) fixed in 
3% paraformaldebyde in PBS for 1 5  min at room temperature or metbanol as 
previously described (Chen et al., 2005 ), washed in PBS tbree times, quencbed with 
50 ruM NH4CI in  PBS for 1 0  min and incubated in permeabi lization/blocking 
solution (0.05% saponin, 0.5% BSA and I x  PBS) for 1 5  min. The fixed cel ls were 
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then incubated at room temperature for 1 h with rabbit polyclonal anti -calnexin 
antibody. After washing with PBS, the cells were incubated with the appropriate 
econdary antibodies (Alexa Fluor 568-goat anti-rabbit IgG) for 1 h at room 
temperature washed se eral times with PBS and mounted in immunofluor medium 
( IC Biomedical ) and visualized under a ikon (UAE University) or Leica ( Imperial 
o l lege London) Confocal microscopes. Images were acquired using Nikon software 
a ciated with the microscope and processed with Adobe Photoshop (Adobe Inc .) .  
All images presented are single sections in the z-plane. 
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CHAPTER I II 
RESULTS 
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3. 1. RESUL TS: Part I 
3 1 . 1 .  t u dy u bj ect 
Three hundred ninety five random blood samples were col lected from UAE 
national pat Ient . The subject recru ited for tho e tudies were derived by two approaches: 
1 .  ubjects [r0111 tbe AI- in Diabete Study ( H u  ein el al. 200 7 ). We cho e 25 patient 
\\ i th tota l  chole terol above 5 nunol 'L which i considered as h igh level of cholestero l .  
2 .  ubJects recruited from the bio hemistry laboratories of Tawam and AI-Mafraq 
ho-pital . their l ip id pro fi le  were reviewed and analyzed for statistical re ul t  . From the 
l Ip id profi le \\ c rc\ ie\\ ed the ( Sex. Age. Total_eboL H D L_c. L D L_c and Tri_G) .  We 
\\ ere concemed about the total cholesterol and the LDL _ c levels, as markers for the FH 
patient a \\ e l l  as the age. Among the inve t igated random ample 300 were female and 
95 male. the maximlU11 age was 84 year old and the minimum was 2 years old with mean 
of 47 )-ear o ld .  Among thi group of patient , we found that the mean of the total 
cholc terol to be 4. nunoVL which can be con idered as risk case, as i t  is hown in the 
table 6 belo\\. : 
Total  cholesterol 395 2 .50  mmol/L 1 0 .30 mmollL 4 . 86 1 4  mmollL 
A ge 395 2 years 84 years 46.6 years 
L D L  C 395 0. 07 nunollL 5 . 1 8  nU1101lL 2.575 nunollL 
Table  6. Samp les detai ls ;  hows the Min ,  Max and the mean age. tota l cholesterol and 
L D L_C level among the study sample 
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Figu re 1 6. Age among the  study pat ient ;  Shows a h istogram for the age among the 
ercened ample , the ample have a erage age of 46. 
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To tcho l e ste ro l 
Figure 1 7. Cholesterol a m o n g  the  S t u dy pat ient ; Shows the cholesterol l evel among the 
selected sample , most the sample have total cholesterol level between 4 to 7 which is considered 
h igh among the screened ample. 
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Figu re 1 8. Data of  the  study pat ient ;  Show the M ax,  Min and mean data of the study 
paticnt ( age, total ehole teTol and L D L  _ C )  
From the random screening fOT the 395 amples the l ipid profiles shows that there 
1 a direct rclation hip bctwecn the age and the ehole teTol level ,  as age increase the level 
of  cholc tcro !  increa e . Figu re ( 1 9 ) below hows the con-elation betwecn the age and the 
total cholestcrol Ie e l .  
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Figu re 1 9. Total  c h olesterol level a mong the s t udy pat ient :  Shows that most o f  the 
patient had total cholesterol levels van e from 4 mmolfL to 7mmolfL and the more the 
age the h igber the total cholestero l .  
3 . 1 .2 .  L D L R  polymorp h is m s  fo u n d  in  U A E  N a tiona ls 
Blood amplcs of U A E  national patients were col lected from the laboratory of 
Tav-. am and Al-Mafraq ho pi ta ls,  su pee ted patients for FH were screened for the 
mutatIon on the LDLR and ApoB l OO gene. D A wa extracted for 40 samples of 
u pected patient and ampl ified by peR and v i  ualized on Agaro e gel electrophoresis.  
pe R product were c leaned with ExoSap enzyme and sent for sequencing by Macrogen 
or cquenced loca l ly  at the Faculty of Medicine and Health Sciences . F igure 20 shows 
typical pe R products prior to DNA sequencing. 
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Typical PeR Proo cts from one subject genomic DNA 
5 6 9/ 
.. 
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Figu re 20. hov. tbe PC R product for the ampli fied cxons of the LOLR gene and the 
po B gene. 
The presence of high levcl of chole terol and the C H O  especial ly  in the young 
p�oplc arc the 1110 t important marker to ident ify the FH patient p lu  the pre ence of 
tendon anthoma, xanthela ma, and arcu corneae a well  as the fami ly history for the 
chole terol level and the C H O .  The forty samples were selected upon the criteria which 
mutch � ith the F H  patient; they were i nterviewed and asked about their fami ly  hi tory for 
the le\ c1 of cholesterol and the coronary heart disease ( C H O) and if  there was any death 
due to C H D  i n  their fir t degree relative . 0 tendon xanthoma, xanthelasma, neither 
arcus comeae v. ere found in our patients except the h igh Ie el of cholesterol and the C H O  
111 ome of  them. Figu re 2 1  shov. s the deta i ls  of the 40 selected patient for the 0 A 
creening and table (7) show the ariou polymorph isms found in ollr subjects. 
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Table  7. Eleven di fferent polymorpbi ms ere found on the LDLR gene in UAE patient . 
The ehromatogram of  tho e pol morphi III are bown in Figu res 22-32 .  
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Figu re 2 1 .  how the Ma , Min  and a erage data of the selected patient ( age, total 
chole terol and L D L_C ) 
Four i lent mutation ( change from amino acid to the same amino acid) were found on the 
L D L R  Exons which are already rcpolied on the LDLR Databa es with no pathogenic 
effect and considered as polymorpbisms, the polymorphisms which were found on the 
exons are summarized in  the table ( 8 )  below: 
r· " 
r - -� � . "_I \ " - - I I�_IL 
, 
crr. 
2c.8 1  
TGT to TGC, 
C)S to C)S -
C6C 
G/A, 
GCC to ACe. 
8c.1 1 7 1 
AJa to Thr -
A370T 
crr, 
1 3 c. 1 96 1  
GIT to GCC, 
\'al to Val -
\632V 
A/G, 
1 5c.2404 
eGG to CGA, 
Arg to Arg 
R7 1 4 R 
\Vild type 
CTCCTTTTCCTCTCTCTC GTGGGCGACAGATGCG��GAAACGAGTTCCAGTGCCAAGA 
sample 
CTCCTTTTCCTCTCTCTCAGTGGGCGACAGATGTGAAAGAAACGAGTTCCAGTGCCAAGA 
1.,ld type 
AGCTGGACCCCCACACGAAGGCCTGCAAGGCTGTGGGTGAGCACGGGAAGGCGGCGGGTG 
sample 
AGCTGGACCCCCACACGAAGACCTGCAAGGCTGTGGGTGAGCACGGGAAGGCGGCGGGTG 
wild type 
CTGTCCCCAGAGGATATGGTTCTCTTCCACAACCTCACCCAGCCAAGAGGTAAGGGTGGG 
sample 
CTGTCCCCAGAGGATATGGTCCTCTTCCACAACCTCACCCAGCCAAGAGGTAAGGGTGGG 
WIld type 
CAGGCTAAAGGTCAGCTCCACAGCCGTAAGGACACAGCACACAACCACCCGACCTGTTCC 
sample 
CAGGCTAAAGGTCAGCTCCACAGC GTAAGGACACAGCACACAACCACCCGGCCTGTTCC 
Table 8. Shows the polymorphisms which have been found on the LDLR Exons 
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H i  togram of the  polymorphic variant  found in o u r  u bj ect ; 
D cqucncing hromatogram how the Het rozygotes, Homozygote , and 
the \\ ild type of each polymorphi 111 . The figure 22-32 bclO\ how the polymorphi 111 
that ex! t on the LDLR gene: 
2c. 8 1  
A O  A T o e G A A A O  
A 0 T O N G A A A O 
.-. 0 • ....,. T G T O r. A ...... 0 
Wild type 
CIC 
Heterozygous 
CIT 
Homozygous 
TIT 
Figu re 2 2 .  S i lent  m u tat ion on exon two (2c.8 1 ) : Show a s i lent mutation on cxon two 
( 2e .8 1 )  \\ hieh is C to T, in the po it ion 8 1  of the coding region of the L D L R  thi change 
from TGC to TGT, leads to a change of Cystci n  to Cyste in - C6C on L D L R  protein. 
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Sc. t t 7 t 
C O  A A O o c e  T O C  
e G  A A G  N e e T G e  
Wild type 
GIG 
Heterozygous 
G/A 
Figu re 23.  S i lent  m u tat ion on exon eight (8c. 1 1 7 1 ) : Show a i lcnt mutation on exon 
eIght ( 8c . 1 L 7 1 )  � hich i G to A.  in  the postion 1 1 7 1  of the coding region of the LDLR 
lh l  change from GCC to  ACe. lead to  a change of to  Alanine to Threonine - A3 70T on 
L D L R  prote in .  
6IVS+36 
T T G T G G G G A G C 
T T G T G N G G A G C 
Wild type 
GIG 
Heterozygous 
G/A 
Figu re 24. Polymorp h is m  i n  the  posit ion (6 I VS+36) : Shows a polymorphism in the 
I ntervening Sequence of exon 6 change from G to A in the position (6 IVS+ 36) .  
- 55  -
7 IVS+I 0 
T T C C C C G G  T G G  
�\A 
T T C C C G O O  T O O  
�� 
Wild type 
C/C 
Homozygous 
GIG 
Heterozygous 
C/G 
Figu re 25.  Polymorph ism in  the posit ion (7  I VS + 1 0 ) :  Sho s a pol ymorphism in the 
I nten cning Sequence of exon 7change from G to C in the po it ion (7 IVS + 1 0) .  
l O IVS-30 
C C  T O  0 T O C T O A 
fJ\d\MWN\ 
C C  T G G C G C T G A 
I I 
C C  T G G N G C T O A 
Wild type 
TIT 
Homozygous 
elc 
Hete rozygous 
TIC 
Figu re 26. Polymorp h i s m  i n  the  p osi t ion ( 1 0  I VS -30 ) :  Shows a polymorphism in the 
I ntervening Sequence of exon 1 0  change from T to C in the position ( 1 0 I VS -30) .  
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l l IVS+53 
A C  T C C C G C C A A  
Wild type 
CIC 
T c e  N G C C A A  
J 
1\(\ Heterozygous 
{ , CIT 
Figu re 27.  Polym o r p h i s m  i n  the  posi t ion ( 1 1 I V S  + 53 ) :  Shows a polymorphi In in the 
lntcf\ cning Sequencc of exon 1 1  in the position ( 1 1  IVS + 53 ) change from C to T. 
l 1 IVS+88 
C ..... G A C G G G G G  
\ 
G G G G G 
Wild type 
CIC 
Heterozygous 
CIT 
Figu re 28. Polymorp hism in the p osi t ion ( 1 1 I V S  + 88) :  Shows a polymorphism in the 
I ntervening Sequence of exon 1 1  in the position ( 1 1 IVS + 8 8 )  change from C to T. 
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1 3c. 1 96 1  
A T G G T T C T C T T  
A T G G T N C T C T T  
Wild type 
CtC 
\ Heterozygous 
CIT 
A T G G T C C T C T T  
NMNwNJ) 
Homozygous 
TIT 
Figu re 29. S i lent  m u tat ion on exon 1 3  ( 1 3e. t 961  ) : Shows a s i lent mutat ion on exon 1 3  
( 1 3c . 1 96 1 )  "" hlch i s  C to T. i n  the position 1 96 1  o f  the coding region o f  the L D L R  thi 
change from GTT to GCC, lead to a change of Val ine to Val ine - V63 2Von LDLR 
protem. 
1 5c. 2404 
A C C C G G C C T G T 
�MfWWjfj ill 
" C C C G N C C T G T 
10NvWtMVJ 
A C C C G A C C T G T 
l
A
MMr\Mfl
� 
W i l d  type 
GIG 
Hete rozygous 
GIA 
Homozygous 
AlA 
Figu re 30. S i lent  m u tat ion  on exon 1 5  ( 1 5e.2404) : Shows a s i lent mutation on ex on 1 5  
( 1 5c .2404) which i A to G,  in the position 2404 of the coding region of the LDLR,  thi 
change from the codon CGG to CGA, leads to a change of , Argin ine to Arginine -
R7  L 4R on L D L R  protein.  
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1 6 IVS+46 
C C  T C C C G C T A T 
C C  T C C N G C T A T 
Wild type 
CIC 
Heterozygous 
CIT 
Figu re 3 1 .  Polymorphism in the posi t ion ( 1 6  I VS + 46): Show a polymorphism in  the 
I nten cnmg Sequence of exon 1 6  in the po it ion ( 1 6  I VS + 46) change from C to T. 
1 8 IVS+98 
T C G C C G G C C  T T 
T C G C C N G C C  T T  
Wild type 
GIG 
Hete rozygous 
GIA 
Figu re 32 .  Polymorphism i n  the p os i t ion ( 1 8  I VS + 98):  Shows a polymorphi m in the 
I ntel' ening Sequence of ex on 1 8  in the position ( 1 8  IVS + 9 8 )  change from G to A .  
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The polymorpbi m � hieh ha\ e been reported in E patient are already known 
polymorphi m' and ha\ e been report d in different popUlation , table ( 1 0 )  bela",,, ho\ 
the polymorphl  m that have been found in UAE population and it pre\alcnee in other 
popu lations . 
1 1 1 \' +88 
1 3c. 1 96 1  
l Sc.2404 
GGCTGG GG 
GGGTTG AGGTG 
G CITGG 
-EU ROPE 
-E ST A I 
AL 
C C G G T TGGTT/CCTC -EAST S I  
TTC CA CCT -EUROPE 
GC C AC ACC CCCGGI ACCT 
GTTCCCG CACC 
- ORTH AMER ICA 
-M U LTf- ATIO AL 
-EAST ASIA 
-CENTRAL/SOUTH 
A M E R ICA 
-E U ROPE 
-WEST A F R IC 
- ORTH A M E R ICA 
1 6 1 \'S+46 CAGGTCACAGCCTCCCITGCT -EUROPE 
ATGTG CCTCGT 
1 8 1 VS+98 TCCTGAGACCTCGCCG/AGCC 
TTGTTTTATTC 
-EAST AS IA 
-MULTI-NATIO A L  
A M E R [CA 
-EAST AS IA 
- ORTH A M E RICA 
-E U ROPE 
-WEST A F R ICA 
T C  
PC 
T C  
CIT 
C T  
CIT 
CIT 
A/G 
G 
G 
A/G 
TIC 
TIC 
A/G 
AJG 
A/G 
A/G 
Table 9. Al lele Frequency for SNPs foundcd in U AE population and its prevalence in 
othcr populations 
From the table we can see that the pol ymorphisms which have been reportcd in  
our patient arc already known polymorphisms and havc been rcported in  somc other 
populations l i ke Europe, East Asia, West Africa, NOlih, south and Ccntral America, and 
some were con idered as mult inationals polymorphi m .  
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3.3 RESUL TS: Part II 
3.3.1 Cel lu lar trafficking of LDLR FH-cau sing mu tation 
We were unable to ident ify any c lear pathogenic mutations in LDLR or ApoBJOO 
gene coding exons that we sequenced in any of the forty one UAE hypercholesterolemic 
ubject . We were expecting to find mutations in up to 30% of hypercholesterolemic 
patients. Thi extrapolation i based on reports from other populations. Therefore for the 
ake of the is ex pan ion and completion; we decided to establish the cellular mechanism 
of orne of the previously reported mutations found in different domains of the LDLR 
protein. 
3.3.2. Expression of wi ld  type and FH -causing LDLR mutants in B eLa cells 
Correct folding of the polypeptides within the Endoplasmic Ret iculum is very 
important and critical for protein function, assembly as well as secretory pathway. 
Retention and ER associated protein degradation (ERAD) of misfolded protein in the ER 
lumen is a cellu lar quality control system ensuring that only properly folded and 
a sembled proteins complex are transported to their final destination (Ali  et at, 2007). 
This  process has been shown to be the underlying mechanism of numerous human genetic 
diseases including many LDLR mutations causing famil ial hypercholesterolemia (Ali ef 
al 2007) .  Different classes of LDLR mutation are associated with famil ial 
hypercholesterolemia. Therefore, we tested the subcellular localization of some of the 
mutant protein LDLR. Very often loss of function in ERAD diseases is due to trafficking 
defects rather than loss of protein biological activity. Therefore, elucidating the cellular 
mechanism is important since ERAD has become important for therapy of this disease. 
FH is suspected to be caused due to trafficking defects in the LDL-receptor. 
Seven different missense mutations in the LDLR cDNA ( P664L, C646Y, G525D, V502D, 
D283N, E207K, E80K; P lease see table 1 1  for details of those mutations) in mammal ian 
expression vector were generated using quick-change PCR based site directed 
mutagenesis and introduced into mammalian cultured cel l l ines using liposome based 
transfection reagent. The subcellular locations of the transiently and stably expressed 
protein were visual ized and evaluated using Confocal Microscopy. 
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G '" ,It 301  L,'OK E, o 0 repeat 2 FH Lancaslme French, Spanish: 
German: lnsh 
2 G A at 1 50� \ 502D E I O  -02 EGF pacer FH KuwalL Ban-} 
Korean 
n 
I G A .It 9 1 0  D2�J E6 2 3 repeat 7 FH DcO\ cr-2 
( b lack), lnsh; Dutch 
4 G . ",  at 2000 C640, E 1 4  646 repeat C 
Canadlan-:'. panlsh 
5 C T at 2054 Po64L E 1 4  664 repeat C worldwide recurrcnt 
Froslnol1cl 
F CanadTan-3 Italian, �lcxlcan, Dutch, 
E20"K E4 207 rcpeal 5 
;\Iodcna French. Chinese; 
Amenn (indian) 
Table 1 0. M utation designed for the t issue culture 
M utagenesis primer table ( 5 )  were designed for thc fol lowing mutations : ( p664L, 
C660X. C646R. G525D. V502M.  D283N, S 1 56L .  E207Q, C88F. E80 K )  and used to 
generate mutant p lasmid that carry GFP-Plasmid for each mutation of the LDLR, aftcr 
that competent cells were transfomled and p lasmid DNA was cxtracted and sequenced to 
confonn the pre ence of each mutation. TI1C p lasmids were transfected into HeLa cells by 
u ing FUGENE6 tran fection protoco l  and incubated unt i l  confluency reached 1 00%. 
Cel l then were visual ized using the Nickon Confocal M icroscope in FMHS or Imperial 
Col lege London for the localization of the protein express ion. TIle fol lowing figures 
show the GFP expression for each mutation : 
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Locali:.ation of the wild type protein 
el l  v. ere lixed and inununolabel led with the anti-ealnexin (an e tablished ER 
marker) polyclonal ant ibodie . ImmunoOuore eenee analy i how the local ization of 
L D LR -G FP \\ t 1d  typc protein on \ aJiou part of the cell ( left pane l )  including the pia ma 
membrane, endopJa mie reticulum and pcrhap th endoeytie sy tem. 
Figu re 33. The exp ress ion of  the G FP in  the wild type in H e La cel l s . HeLa eclls were 
tran feeted 'v\ ith c-term i nal ly  GFP-tagged LDLR wi ld type constructs. Figw-es show thc 
except IOn of the L D L R  protein on the cell surface, this is expected inee the p lasma 
membrane located fraction is the matW'e one and the ER i the newly synthe ized. The 
cndoc)t ic fract ion of the protein (smal l  esicle in  the cel l )  is  probably involved in 
endocytosis .  
Locali:.ation of E80K mutant 
E80K i a novel mutation in the LDLR gene due to change from G to A at the 
po it ion 30 1 on E xon 3 which span the second repeat of the Cystein rich sequence 7 
repeat of the l igand binding domain .  This mutat ion is reported to be F H  Lancashire with 
American,  Engl ish ,  French, Spanish, Gennan, N .  Irish ethnic Origin .  M utations in l igand 
binding domain arc con idcred a Class 3 Binding-Defective Al leles m u tat ions.  In this 
c lass of mutation the receptors reach the cell surface but arc defective in  l igand binding. 
H O'v\ ever. cia 3 mutation are categorized i n  that the L D L R  arc sti l l  able to perfonn 
intracel lu lar transport .  This is mostly due to in-frame reanangements in the cy tei ne-rich 
repeat of the l i gand-binding-domain of the L D L R  or the adjacent growth factor repeats 
of thc Epidem1al Growth Factor ( EG F )  precW'sor domain 
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Figu re 34. Local izat ion of E80K m u ta n t  i n  H el a  Cells .  [t IS c lear that the mutant 
protem 1 cxpre ed only in the E R .  
L ocali:.atiol1 of the £20 K L DL R  mutant 
E207 K i a novel mutation in the LDLR gene due to change from G to A at the 
po !t ion 6 2 on Exon 4 which span the fifth repeat of the Cystein rich sequence 7 repeats 
of the l igand binding domain This mutation i reported to be F .Canadian-3!Modena with 
French-Canadian;  I ta l ian;  1 cxiean; Dutch: French:  Chine e;  S .African ( Indian ) Ethnic 
Ongen. thi  mutation al  a is  considered as Cl ass 3 Binding-Defect ive A lleles m u tat ions. 
Where the L D L R  i t i l l  expre cd on the surface of the cel l  but hav ing defect with 
binding to the LD L part ic le from the figure i t  is c lear that most a f the LD LR are reta ined 
10 the E R  and not expressed on the cel l  surface. 
Figu re 35.  Local izat ion of  E 207K m u tan t in H el a  Cells. I t  is clear that the mutant 
protein is reta ined in the ER and not expressed on the cell surface. 
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Local;';'atioll of D283,v LDLR mutant 
02 3 i a no cl mutat ion in thc LDLR genc duc to change from G to at tbc 
po I l ion 9 1 0  on Exon 6 v, hich pan thc 7th repeat of thc Cystc in rich equence 7 repeat 
of the l igand binding domain Thi mutation i reported to be FH Denver-2 with Afrikaner, 
American ( b lack).  Iri 11 , Dutch Ethnic origin .  Thi mutation al 0 i considered a Class  3 
B i n d i ng-Defect ive Al le le  m u tat ion . Where the L D LR i t i l l  e pressed on the urface 
of the cc l l  but ha\ ing defcct with binding to tbe L D L  part ic le . 
Figure 36.  Local ization of the D283N mutat io n ;  The figure how that there no 
L D L R  exprc cd on the cell urface and a l l  arc retained in the ER .  
Locali:ation of V 502,\1 L D L R  mutant 
V502 M is a novel mutat ion in the L D L R  gene due to change from G to A at the position 
1 5 67 on Exon 1 0  which span the cpidennal growth factor ( EGF)  precursor, This mutation 
i s  reported to be FH Kuwait, Bari-2 with Kuwait i ,  I ta l ian, Dutch, Korean Ethnic origin .  
Epidennal grov.1.h factor ( EGF)  precursor domain is requi red for the di  sociation of 
l i poprotei n  from the receptor in the endosome during receptor recycl ing. I t  also scrves to 
po ition the l igand binding domain 0 that i t  can bind L D L  on the cel l  surface .  From the 
figure above we can see that this mutation leads to a complete retained of the LDLR in 
the ER wi th no excerption on the cel l  urface. 
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Figu re 3 7. Localization of the VS02 M m u tat ion :  It i c lear that the mutant protei n is 
retamed in the E R  and not expre cd on the cel l  surface. 
L ocali;.ation of G525D L DL R  III lltant 
G525D is a nov el mutat ion in the L DLR gene due to change from G to A at the 
po it ion 1 63 7  on Exon I I  \\ hich pan the epidermal growth factor (EGF)  prccur or, Thi 
mutatIOn i rcpoI1ed to be with French ethn ic origin, epiden11al growth factor ( EGF)  
precur or domain is  required for the dis ociation of l ipoprote ins from the receptor in the 
cndo orne during receptor recyc l ing. It al a serves to position the l igand binding domain 
a that It can bind L D L  on the cel l  surface. The figure haws no expression of the LDLR 
on the cel l urface and al l arc retained i n  the E R .  
Figu re 3 8 .  Local ization o f  G 5 2 5 D  m u tation ; I t  i c lear that the mutant protein IS  
retained in  the ER and not expressed on the cel l  surface. 
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Locali"ation of C646 Y LDLR mutant 
6�6Y l' a no\ el mutat ion in the LDLR gene due to change from G to A at the 
po ition 2000 on E on 1 4  which pan the repcat C of the epidermal growth factor ( EGF)  
preeur or domain, Thi  mutation i reported to  be FH  French Canadian-2 with French 
anadtan, Dutcb, pant h ethnic origin .  The figure hovy no exprc sion of the LDLR on 
the cel l  urface and al l  an.: retaincd in  the ER. 
Figu re 39. Loca l izat ion of C6�6 m u tation ; I t  i c lear that the mutant protein i rctained 
in the E R  and not expres ed on the ccl l  surfaec ,  
Localhatiol1 of P664L L DL R  mutant 
P66�L i a no\ c l  mutation in the LDLR gene due to ehange from C to T at the 
position 205� on Exon 1 4  which span the repeat C of the epidermal growth factor ( EGF)  
precur or domain, TIl is mutation i reported to  be  FH  GujaratiFrosinone I and is found 
world\\ ide. The figure hows no cxprcs ion of the LDLR on thc cell surface and a l l  are 
retained in  the E R. 
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Figu re 40. Local izat ion of P664 L m u t atio n ;  It is c lear that the mutant protein is retained 
In the E R  and not expre ed on the cel l  urface. 
The mo t frequent type of mutation on the LDLR is the EGF homology domain 
mutation . \\ hieh i con idered a c lass 3 mutat ions, where the receptor reach the cell 
urfacc but are defe t ive in  l igand binding. However. clas 3 mutations arc categorized in  
that they t i l l  arc able to pcrfonn intracel l ular transport. Thi i mo t ly  due to a result of 
i n-frame rearrangement i n  th Cystein-rieh repeats of the l igand-b inding domain of the 
L D L R  or the adjacent growth factor repeat of the Epidennal Growth Factor ( EGF)  
precursor domain .  The mutation on  the LDL R-EGF H omology domain result with 
meorrcct folding for the L DL R in the Endoplasmic Reticu lum which lead to the 
protein being retained in the ER and w ith l i tt le expressed protein on the cel l urfaee as it 
i c lear in figure abo\e. 
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DISCUSSION 
AND 
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4.1 .  D I SC U SS I ON 
FH i a common auto oma] dominant disease cau ed by mutations in the LDLR, 
ApoB 1 00, and PCSK9 gene or due to other unidentified genetic factors. So far, more than 
1 600 different mutations ha e been reported on the LDLR gene which causes FH. Those 
mutations ary between sub titution, deletion, in ertion and inversion mutations. The 
mo t frequent type of mutat ion i the substitution mutation which occurs mostly in the 
EGF precur or homology domain. (http://www .ucl .ac .ulJfh). 
FH is one of the most common genetic disorders in the world population as it 
affects 1 in 500 people. The UAE is a mixture of Arabs, Asians, Persians and other 
smaller minorities. Therefore, the prevalence of FH in the UAE is expected to be at least 
simi lar to the rest of the world. In addition, biochemical data (Agarwal et el. , 1 995) 
indicated a high prevalence of this condition among the Arab inhabitants of the UAE. 
Therefore, this study was designed to initiate the identification of the molecular defects 
underlying the condition in UAE. For this purpose three hundred n inety five random 
blood samples from UAE national patients were reviewed for their lipid profiles. From 
their profi les we ound that the mean of the total cholesterol was 4. 864 which is 
considered to be high. It is  clear from the statistical result that the UAE population has 
h igh level of cholesterol due to the food and the l ife style in the area which is mainly 
heavy of fats and with low exercising. Many of the patients are on statin treatment to 
lower their cholesterol .  We did not find molecular defects in our subjects with 
hypercholesterolemia. This may indicate that the prevalence of FH is low in the UAE 
population and therefore hypercholesterolemia is due to other genetics factors and/or 
environmental factors including l ife style and diet which is known to be very rich in 
saturated fats. In addition, l ife style in the UAE has changed in the last 30 years with 
more sedentary l ife style and l imited exercise. 
Although we interviewed the patients and we believe that they gave us the correct 
data about themselves and their relatives regarding their cholesterol levels and CHD in 
their family and relatives and in most cases we would see a famil ial l ink of their high 
cholesterol levels, we were unable to find any mutations in the regions we sequenced. 
This was surprising to us because we were expecting about 30% to be caused by 
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mutations in the LDLR or ApoB I 00 genes. For example, the pedigree for one of the 
candidate who was strongly believed to have FH is shown in figure (4 1 ) . As can be seen 
From the diagram, se eral members of this pedigree ha e a history of high 
cholesterol and CHD; four of the second generation has high cholesterol and two of the 
children al 0 have high chole terol levels. However DNA sequencing of the index case 
of this pedigree did not reveal any pathogenic mutations. 
67 
� Hypercholesterolemia Male 
i Hypercholesterolemia Female 
63 60 57 
26 
53 49 
22 17 16 
Figure 4 1 .  Shows the pedigree of one of FH candidate subjects. 
From the 40 samples which have been tested for LDLR and Apo B 1 00 mutation, 
1 1  d ifferent polymorphisms have been founded on the LDLR gene but there were no 
mutat ions or polymorphisms reported on the ApoB 1 00 (exons 26 & 29) gene. Those 1 1  
polymorphisms are reported in different databases and with known ethnic backgrounds 
such as; Europe, East Asia, West Africa North, south and Central America, and some 
were considered as multinational polymorphisms. We report here (table 1 2) the frequency 
of each allele in our group of subjects. 
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CIC 60l7£ A l lele Freq uency 
2c.8 1 
CIT. TGT to TG .Cy 
CIT 3 7 . 5 %  C T 
to Cys - C6C 
TIT 2 .50o/c 78 .75% 2 1 .25% 
GIG 95% A l lele Frequency 
GI A, GCC t o  ACe, Ala 
8c . 1 1 7  I t o  GIA 5 %  A G 
Thr -A3 70T 
AlA 0% 2 .5% 97 .5% 
GIG 85% A l lele Frequency 
6 IV +36 AlG G/A 1 5 % A G 
AlA 0% 9 2 . 5 %  7 . 5 %  
GIG 20% A l lele Frequency 
7 IV S + I O  GIC GIC 60% C G 
CIC 20% 50% 50% 
CIC 20% A l lele Freq uency 
l O IV S -30 CIT CIT 62.50% C T 
TIT 1 7 .50% 5 1 .25% 48 .75% 
CIC 9 2 . 50% A l lele Frequency 
1 1 I V S+5 3 CIT CIT 7 . 50% C T 
TIT 0% 96.25% 3 . 75% 
CIC 75% A l lele Frequency 
1 1 IVS+88 CIT 
CIT 25l7£ C T 
- 7 3  -
T 0% 87.5% 1 �.5  
CIC 1 7.50% Al lele Frequency 
1 3c. 1 96 1  
CIT, GTT to GCC, 
CIT 57.50% C T 
al to Val - V632V 
TIT 25% 46.25% 53 .75% 
GIG 52 .50% Allele Frequency 
1 5c.2404 
G, CGG to CGA, 
GIA 42.50% A G 
Arg to Arg R7 1 4R 
NA 5% 26.25% 73 .75% 
CIC 60% Allele Frequency 
1 6IVS+46 CIT CIT 40% C T 
TIT 0% 80% 20% 
GIG 67.50% Allele Frequency 
1 8IVS+98 GIA GIA 32.50% A G 
NA 0% 83 .75% 1 6.25 
Table 1 1 . Shows the present of each polymorphism and the allele frequency. Al lele 
frequency was plotted as shown in figure 42 for simplifying the presentation of the data. 
During the search for cases of FR in the hospitals we did not find any case which 
was homozygous for FR,  which supports the idea that our country is free from mutation 
on the LDLR gene. The high prevalence of the hypercholesterolemia in the same family 
could be due to other genetic factors and the fact of high percentage of consanguinity 
married could be another strong reason for the prevalence of high cholesterol among the 
same fami ly or it could be due to other environmental factors. 
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lDlR2:tJl 
LDlR7IVSHO 
lDlR lllVSt88 
lDlR8c.lln 
1.50% 
lDlR 10lYS-30 
trulk1961 
IDlR 161VSt46 
• "" Fr91uencyC 
I,," Fr91uenty T 
83.75% 
7.50% 
trulllVSt53 
3.75% 
I Ali! Fr91u� T 
lDlR l5c.2404 
Figu re 42.  Show the frequency of each a l lele 
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Effect of some mi  en e mutations on the cel lu lar localization of  the  LDL-Receptor 
As hown on figure 1 2, LDLR is  a plasma membrane localized receptor. However, 
it is fir t syntbe ized on ribosomes attached to the cytosolic side of the endoplasmic 
ret iculum. The protein tben traffics through tbe secretory path to the plasma membrane 
and then used for endocytosis to transport the LDL particle into the cell .  All these 
trafficking teps are es ential for tbe proper functioning of the receptor therefore failure of 
any step wil l  lead to loss of function and the development of FR.  Therefore as an 
extension to our molecular studies on the identification of tbe molecular causes of 
hypercholesterolemia in UAE, we decided to study tbe effects of some missense 
mutation on the trafficking of LDLR in cultured cell l ines. We generated a number of FR 
pathogenic mis ense mutations by site-directed mutagenesis and expressed tbe proteins in 
ReLa cells for comparison of the wild type with the mutants. Tissue culture results shows 
tbat several mutations in the LDLR gene in the EGF precursor domain leads to possibly 
incorrect folding of the protein resulting in fai lure of the receptor to reach i ts final 
destination. This mislocal izations was suspected due to differences in the apparent 
location of the wild type protein and the mutants and also due to co-local isations of some 
of the mutants with an established ER marker (calenexin). These preliminary data will  
serve as a stimulus for further studies on this receptor in the laboratory. This is especially 
important because we suspect that many of the missense mutations might not affect tbe 
receptor binding to its l igand but they lose the function because they are in the wrong 
location within the cel l .  Therefore, correcting that localization might lead to the 
development of new therapies for FH. This is a plausible approach especially in the l ight 
of the finding that it might be possible to overcome ER-retention for therapy of ER 
misfolding diseases (Romisch, 2004; Cohen and Kelley, 2003 ). 
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4.2 .  C O N C LU S I ON S  
everal major conclusion could b e  drawn from the present work: 
( i )  AE population has high levels of cholesterol and therefore many subjects are at 
high risk of de elopment eVD 
i i )  The prevalence of LDLR and ApoB l OO FH-causing mutations among DAE 
hypercholesterolemic subject seems low or absent. 
i i i )  The high chole terol levels in the UAE population might be due to l ife style 
inc luding high intake levels of saturated fats or it might be due to some other 
unidentified or unstudied genetic factor(s) 
( iv)  Further studies are urgently needed to elucidate the exact causes of 
hypercholesterolemia in DAE population 
(v) We report a range of polymorphisms III the LDLR gene in the DAB 
hypercholesterolemic subjects. Those polymorphisms are present in European, 
East Asian, West African and American population which may help in LDLR 
haplotype studies. 
(v i )  Loca lization of some LDLR mutat ions indicate incorrect folding and trafficking 
of LDLR. Some of those missense mutations resulted in the retention of the 
mutants receptor in the endoplasmic reticulum raising the possibility of USlllg 
this as a new drug target for FH and other ER-misfolding diseases 
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5 .  ppendix I 
Patient  I n fo r m a t i o n  S h eet 
PROFOR lfA FOR ISFORMA TIO.\ PURPOSES O. L Y  
You are ll1\lted to tak!: pan III a re earch tud} entllied. The genetic bas is  of fa mi l ia l  
h. 'perchole terolemia  i n  the U n ited A ra b  E m i rate . Before you decide i t  I S  Imponant to 
under tand ''vh} the re careh is bemg done and � hat it \'v l l l lll 'v o l 'v e. 
Thl: a i m  o f  this tudy i to ident ify ind ividu a l s  from the U A E  pop u lat ion with 
h igh  chole terol levels  a n d  establ ish if  their  h ypercholesterolemia is  due  to 
genetic factors. 
The duration of the project i 2 years. Patient wi th i n herited h igh 
chole terol levels in the ir  b lood are included in th i  study. 
i/you decide to take part you will be given this in/ormation sheet to keep and be a ked (0 sign a 
consent form. and you will remain free to withdraw at an)' time without gil·ing a rea on. This will 
flot a//ecr the standard 0/ care YOIl receive. 
You � I 1 1  be i m oh ed in the research only once and a mall ample (about 1 0  m l :  2 tea poonful)  o f  
blood \\ I I I  be obtained. There � i l l  be n o  additional r i  k . 
There \\ I I I  be no He\\ drug. nor any ne\\ procedure to be tested. Studie on your blood sample wil l  
idenl lf) if your hIgh chole terol le\ el' are due to genetic factor . TIllS "" i l l  help the doctors decide and 
impro\ e on the cour e o f  your future treatment. ThIS will al  0 help to determine i f  members o f  your 
famil)  are at nsk of de\ clopmg cardim ascular i Une due to mheflted hIgh chole tero l levels. 
All 1Il [ormatlon \\ hlch I collected about you will be kept strict ly confidential .  An infonnallon 
about you which leave the ho pital � i l l  hav e your name and address removed so that you cannot be 
recognlLed from It .  
The doctor and re earcher conducting lhi re earch arc not bcing paid for worlang on this 
re earch project.  
For Further I n formation. you can conta t :  Dr.  Ba sam R.  Ali.  Unitcd Arab Emirates Univ ersity 
Faculty of Medicine and Health SCIences. Department o f  Pathology. r .O. Box 1 7666. A I -Am, AE 
Tel. -97 1 3 7 1 37470. Mobile:  +97 1 50 5734708. Fax +97 1 3 767 1 966 
or Dr. E isadiq KaLLam 
Thank you \ ery much for taking part in thi study. 
Date 
(111C patient w i l l  bc given a copy of th i  sheet and a signed consent fann to keep. ) 
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Ho pital arne: 
Study number: 
Patient ID number used in the study: 
I N FO RM E D  C O N S E N T  FORM 2 
Title of project :  The genetic basis of fami l ial hypercholesterolemia in the United 
rab E mi rate 
Name of researcher : 
Dr. Ba sam Ali, Associate Professor of Molecular Genetics, Faculty of Medicine and 
Health Sciences, UAE Univer ity 
Dr. EI adeq E. Kazzam, Associate Professor in Clinical Cardiology, Facul ty of Medicine 
and Health Sciences. UAE University 
Shaikha Al-Mazrooei, Master Student, UAE University 
I conflrm that I have read and understand the information sheet dated . . . . . . . .  . 
( ersion . . . . .  ) for the above study and have had the opportunity to ask questions. 
:2 I understand that my participation is voluntary and that I am free to withdraw at any 
time 
3 I understand that if I withdraw from the study it wil l  not adversely affect my 
healthcare or employment 
4 I understand that my data will  be kept confidential and in a safe place 
5 I agree to take part in the above study 
Name of patient Date 
arne of person taking consent Date 
arne of witness (if subject Date 
unable to read/write) 
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Signature 
Signature 
Signature 
APPENDIX II 
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6 .  Appendi x  I I  
2 Female 56 6.00 No 1 . 34 4 . 1 4  1 . 1 3  
3 Female 57 6 . 1 0  ye l . 1 5  4 .39  1 .23 
4 Female 55  6 . 1 0  No 1 .46 4.08 1 .23 
5 M ale 40 6. 1 0  No 0 .89 4 .77 0 .97 
6 Female 65 5 .80 No 1 .00 4 .36 0 .97 
7 Female 43 5 .20 No 0 .85 3 . 86 1 .07 
8 Female 32 5 . 1 0  yes 1 . 1 7  3 .45 1 .05 
9 Female 40 5 . 70 No 1 . 62 3 . 86 0.47 
1 0  Female 65 8 .90 yes 1 . 1 0  6 .70 2 .39 
I I  Female 45 6 .60 No 1 .4 1  4.49 1 .52  
1 2  Female 40 6.40 No l . 36 4 .7 1 0.72 
1 3  Female 37 5 . 70 yes 0.96 4 .36 0 .83 
1 4  Female 46 7 .90 No 1 . 1 2  6 .37  0.90 
1 5  Male 30 6 .00 yes 0 .79 4.62 1 .29 
1 6  Female 40 6 .30 No 1 .23 4 .69 0 .83 
17 Female 27 5 . 80 No 1 .40 3 . 97 0 .94 
1 8  Male 70 6 .60 No 1 .42 4 .67 1 . 1 2  
1 9  Female 30 5 . 80 ye 1 .08 4 .28  0 .97  
20 Female 39 6 .40 No 1 .0 1  4 .48 1 .98 
2 1  Male 43 5 . 30 yes 1 . 26 3 .4 1 1 .37  
22  Ma le 50 5 . 70 No 0.6 1 4 . 1 5  2 .06 
23 Female 49 5 . 40 No 1 . 55  3 . 63 0.48 
24 Male 46 5 . 20 No 0 .82 3 .93 0 .99 
25 Female 55 5 . 30  No 1 .00 3 . 1 0  2 .62 
Table 1 2 . Deta i ls  about the selected patients for sequencing 
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